Harvey Douglas White

Q: What Schools Are Affiliated With Harvey Douglas White

Harvey Douglas White is affiliated with the following schools: Uppsala University, University of Sydney, University of Alberta, University of British Columbia, Queen's University at Kingston, Baylor College of Medicine, United States Military Academy, University of Toronto, University of Washington, University of Auckland, Paris Diderot University, Duke University

Harvey Douglas White's AcademicInfluence.com Rankings

Medical

#643

World Rank

#859

Historical Rank

Cardiology

#27

World Rank

#27

Historical Rank

Public Health

#62

World Rank

#63

Historical Rank

Epidemiology

#77

World Rank

#85

Historical Rank

medical Degrees

Harvey Douglas White

Philosophy

#2584

World Rank

#4371

Historical Rank

Logic

#659

World Rank

#1153

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Harvey Douglas White's Degrees

Bachelors Biology University of California, Berkeley
Doctorate Medicine University of California, San Francisco

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is Harvey Douglas White Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Harvey Douglas White's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. (1998) (5391)
Third universal definition of myocardial infarction. (2012) (4123)
Third universal definition of myocardial infarction (2012) (3338)
Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium (2011) (3111)
Fourth Universal Definition of Myocardial Infarction (2018). (2018) (2724)
Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction (2008) (2680)
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. (2003) (2366)
Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. (1987) (2364)
Universal definition of myocardial infarction. (2007) (2304)
Universal definition of myocardial infarction. (2015) (2234)
Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. (1999) (2210)
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. (2004) (1917)
ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction (1995) (1755)
Universal definition of myocardial infarction. (2007) (1695)
Fourth universal definition of myocardial infarction (2018). (2018) (1537)
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. (2004) (1346)
Bivalirudin for patients with acute coronary syndromes. (2006) (1122)
Initial Invasive or Conservative Strategy for Stable Coronary Disease. (2020) (1071)
Third universal definition of myocardial infarction. (2012) (921)
ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION (1992) (920)
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. (1999) (897)
Apixaban with antiplatelet therapy after acute coronary syndrome. (2011) (872)
Acute Coronary Care in the Elderly, Part I. Non–ST-Segment–Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology (2007) (859)
Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. (2007) (849)
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials (2002) (840)
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. (2004) (833)
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial (2010) (808)
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. (2005) (773)
Third universal definition of myocardial infarction. (2012) (751)
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. (2012) (718)
Effect of platelet inhibition with cangrelor during PCI on ischemic events. (2013) (705)
Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. (1987) (660)
One-year survival following early revascularization for cardiogenic shock. (2001) (642)
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. (2007) (624)
Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. (2006) (611)
Coronary intervention for persistent occlusion after myocardial infarction. (2006) (599)
Intravenous platelet blockade with cangrelor during PCI. (2009) (590)
Platelet inhibition with cangrelor in patients undergoing PCI. (2009) (571)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) (558)
Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban (1999) (543)
Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? (2000) (527)
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. (1995) (507)
Cardiovascular Efficacy and Safety of Bococizumab in High‐Risk Patients (2017) (488)
Sex differences in mortality following acute coronary syndromes. (2009) (483)
Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes (2002) (482)
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. (2012) (481)
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. (2001) (481)
Darapladib for preventing ischemic events in stable coronary heart disease. (2014) (475)
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. (2006) (452)
Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? (2005) (442)
Fourth Universal Definition of Myocardial Infarction (2018). (2018) (429)
Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes (2001) (429)
Acute Coronary Care in the Elderly, Part II: ST-Segment–Elevation Myocardial Infarction A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology (2007) (421)
Third universal definition of myocardial infarction. (2012) (408)
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. (2005) (393)
Inhibition of the Sodium-Hydrogen Exchanger With Cariporide to Prevent Myocardial Infarction in High-Risk Ischemic Situations: Main Results of the GUARDIAN Trial (2000) (393)
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial (2007) (392)
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. (2014) (391)
Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction (1997) (387)
Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial (2001) (376)
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. (1998) (367)
Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (2011) (356)
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. (2006) (352)
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina (1998) (351)
Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. (2009) (344)
Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. (1995) (341)
Association between Polycystic Ovaries and Extent of Coronary Artery Disease in Women Having Cardiac Catheterization (1997) (337)
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation (2016) (331)
Increased Plasma Natriuretic Peptide Levels Reflect Symptom Onset in Aortic Stenosis (2003) (322)
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. (1999) (311)
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. (2007) (304)
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. (1996) (301)
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. (1996) (300)
Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project (2001) (300)
Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? (2011) (289)
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. (2014) (288)
Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. (1996) (271)
Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. (2007) (267)
Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels? (2002) (266)
Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. (2003) (260)
N-Terminal Pro–B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes (2004) (259)
The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. (1992) (256)
A catalog of genetic loci associated with kidney function from analyses of a million individuals (2019) (252)
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial (2000) (252)
Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis Results of the LIPID Atherosclerosis Substudy (1998) (247)
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data (2002) (246)
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. (2004) (246)
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded (1995) (241)
Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. (2003) (236)
Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status: The PARAGON-B Troponin T Substudy (2001) (233)
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. (2012) (231)
Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO) (1997) (229)
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. (2005) (229)
Importance of frailty in patients with cardiovascular disease. (2014) (226)
Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. (1994) (224)
Acute myocardial infarction (2008) (224)
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. (2020) (220)
New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. (2000) (215)
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). (2014) (215)
Comparison of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting After Acute Myocardial Infarction Complicated by Cardiogenic Shock: Results From the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Trial (2005) (210)
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. (2004) (208)
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial (2016) (200)
Significance of Smoking in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction Experience Gleaned From the International Tissue Plasminogen Activator/Streptokinase Mortality Trial (1993) (199)
Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents: The Acute Catheterization and Urgent Intervention Triage Strategy Trial (2009) (197)
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. (2009) (193)
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study (2000) (193)
Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure underpinning obesity (2017) (193)
Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. (1989) (183)
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation (2008) (183)
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1997) (179)
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. (2009) (176)
Efficacy and safety of timolol for prevention of supraventricular tachyarrhythmias after coronary artery bypass surgery. (1984) (173)
Pravastatin therapy and the risk of stroke. (2000) (170)
[Universal definition of the myocardial infarction]. (2008) (170)
Fourth universal definition of myocardial infarction (2018). (2019) (169)
After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptoki (1993) (169)
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients (2018) (168)
2011 Addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes (ACS) 2006. (2011) (161)
Echocardiographic Predictors of Survival and Response to Early Revascularization in Cardiogenic Shock (2003) (161)
Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. (2000) (159)
Thrombolysis for acute myocardial infarction. (1998) (158)
ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial (2008) (156)
Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. (1999) (156)
End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. (1997) (155)
Long-term survival and valve-related complications in young women with cardiac valve replacements. (1999) (155)
Clinical implications of the new definition of myocardial infarction (2003) (154)
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). (2006) (154)
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. (2004) (154)
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. (2002) (152)
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study☆☆☆★ (2002) (152)
Gender and acute myocardial infarction: is there a different response to thrombolysis? (1997) (151)
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. (2009) (149)
Fourth Universal Definition of Myocardial Infarction (2018). (2018) (144)
Sustained Ventricular Arrhythmias Among Patients With Acute Coronary Syndromes With No ST-Segment Elevation: Incidence, Predictors, and Outcomes (2002) (144)
Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial (2017) (144)
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes (2002) (144)
Acute myocardial infarction in the young--the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. (1995) (142)
Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. (2009) (141)
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. (2000) (141)
Prognosis of Patients With Non–ST-Segment–Elevation Myocardial Infarction and Nonobstructive Coronary Artery Disease: Propensity-Matched Analysis From the Acute Catheterization and Urgent Intervention Triage Strategy Trial (2014) (140)
Mortality Within 24 Hours of Thrombolysis for Myocardial Infarction: The Importance of Early Reperfusion (1994) (139)
APPRAISE 2. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome for the APPRAISE-2 Investigators* (2011) (136)
Stent deformation following simulated side‐branch dilatation: A comparison of five stent designs (1999) (136)
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. (2018) (134)
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. (2002) (134)
Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial (2010) (131)
Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization: Insights Into the Safety of Long-Term Dual Antiplatelet Therapy With Reduced-Dose Prasugrel Versus Standard-Dose Clopidogrel (2013) (129)
Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. (2009) (129)
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. (2016) (128)
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. (2009) (125)
A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the SHOCK Trial and Registry. (2010) (123)
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes (2004) (123)
Diagnostic and therapeutic implications of type 2 myocardial infarction: review and commentary. (2014) (123)
One-Year Results From the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) Trial (1996) (122)
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. (2017) (122)
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial (2010) (122)
Postsystolic shortening of acutely ischemic canine myocardium predicts early and late recovery of function after coronary artery reperfusion. (1988) (121)
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal (2007) (121)
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. (2019) (119)
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. (2010) (119)
Prognostic differences between different types of bundle branch block during the early phase of acute myocardial infarction: insights from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. (2006) (118)
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial (2013) (118)
Informed consent during the clinical emergency of acute myocardial infarction (HER0-2 consent substudy): a prospective observational study (2003) (117)
Long-term risk stratification for survivors of acute coronary syndromes - Results from the long-term intervention with pravastatin in ischemic disease (LIPID) study (2001) (117)
Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk. (2006) (114)
Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial (2016) (113)
Plasma Lipoprotein(a) Concentration Predicts Future Coronary and Cardiovascular Events in Patients With Stable Coronary Heart Disease (2013) (113)
Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression. (1999) (113)
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. (2009) (112)
Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? (2000) (110)
Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. (2004) (109)
Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction: Results From the Valsartan in Acute Myocardial Infarction Trial (VALIANT) (2005) (107)
The universal definition of myocardial infarction: a consensus document (2007) (107)
Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. (2007) (107)
Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. (2005) (106)
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial (1997) (106)
Significance of diabetes mellitus in patients with acute myocardial infraction receiving thrombolytic theraphy (1993) (105)
Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction (1996) (105)
Clinical outcomes of bivalirudin for ischemic heart disease. (1999) (104)
End‐Systolic Volume and Long‐term Survival After Coronary Artery Bypass Graft Surgery in Patients With Impaired Left Ventricular Function (1994) (104)
Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking. (1990) (103)
Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. (2012) (103)
The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry☆ (2000) (102)
Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1998) (101)
Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. (2012) (100)
Waiting times and prioritisation for coronary artery bypass surgery in New Zealand (1999) (100)
Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. (2003) (99)
Effect of Alirocumab on Mortality After Acute Coronary Syndromes (2019) (99)
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. (2008) (99)
Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (E (2005) (98)
Effect of six months' exercise training on C-reactive protein levels in healthy elderly subjects. (2004) (98)
Depression and cardiovascular morbidity and mortality: cause or consequence? (2003) (98)
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. (1998) (97)
Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure) (2016) (96)
Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial (2019) (95)
Post-systolic shortening: a marker of potential for early recovery of acutely ischaemic myocardium in the dog. (1987) (95)
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). (2014) (93)
Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. (1999) (91)
Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. (2011) (91)
Left ventricular systolic and diastolic function assessed by tissue Doppler imaging and outcome in asymptomatic aortic stenosis. (2010) (90)
Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. (2005) (89)
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibi (2006) (89)
Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. (1997) (88)
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. (2017) (88)
Impact of Collateral Flow to the Occluded Infarct-Related Artery on Clinical Outcomes in Patients With Recent Myocardial Infarction: A Report From the Randomized Occluded Artery Trial (2010) (88)
Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease (2016) (88)
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context (2003) (87)
Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2017) (87)
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. (2003) (86)
Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). (2009) (85)
Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks. (2005) (84)
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). (2014) (84)
Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. (2005) (83)
Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. (2008) (83)
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. (2014) (83)
Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. (2008) (83)
Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study (2000) (83)
Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. (1992) (82)
Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. (1997) (82)
Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. (2016) (81)
Physical activity in patients with stable coronary heart disease: an international perspective (2013) (81)
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. (2014) (81)
Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. (2009) (81)
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. (2017) (80)
Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. (1998) (80)
D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease: LIPID Study (2018) (80)
Prevalence of factor V Leiden and prothrombin variant G20210A in patients age <50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. (2000) (79)
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. (2006) (79)
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. (2012) (79)
Early noninvasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial infarction. (1998) (78)
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial (2020) (78)
[Fourth universal definition of myocardial infarction (2018)]. (2018) (78)
Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. (2002) (77)
Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2 (2006) (77)
Relation of left ventricular sphericity to 10-year survival after acute myocardial infarction. (2004) (76)
Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. (1995) (76)
The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. (2006) (75)
Clinical and Angiographic Predictors of Short- and Long-Term Ischemic Events in Acute Coronary Syndromes: Results From the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) Trial (2010) (74)
A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. (1994) (74)
The results of surgical treatment of left ventricular aneurysms. An assessment of the risk factors affecting early and late mortality. (1984) (73)
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. (2000) (73)
Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. (2009) (71)
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. (2002) (70)
Survival Outcomes 1 Year After Reperfusion Therapy With Either Alteplase or Reteplase for Acute Myocardial Infarction: Results From the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial (2000) (70)
Serum troponins T and I after elective cardioversion. (2000) (69)
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome (2019) (69)
Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction. (1990) (69)
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. (2005) (69)
A Model for Predicting Mortality in Acute ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Results From the Assessment of Pexelizumab in Acute Myocardial Infarction Trial (2010) (69)
Design and methodology of the Occluded Artery Trial (OAT). (2005) (69)
Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. (2003) (67)
aVR ST elevation: an important but neglected sign in ST elevation acute myocardial infarction. (2010) (67)
PROTEIN-CODING VARIANTS IMPLICATE NOVEL GENES RELATED TO LIPID HOMEOSTASIS CONTRIBUTING TO BODY FAT DISTRIBUTION (2018) (67)
Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. (2007) (67)
Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. (2009) (67)
ST-Segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy. (2000) (66)
Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. (1999) (66)
Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. (2008) (66)
Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. (2016) (64)
Withdrawal of statins in patients with acute coronary syndromes. (2003) (64)
Antiplatelet drug nonresponsiveness. (2008) (63)
Risk Stratification of Patients With Acute Anterior Myocardial Infarction and Right Bundle-Branch Block: Importance of QRS Duration and Early ST-Segment Resolution After Fibrinolytic Therapy (2006) (63)
Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease). (2014) (62)
Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. (2011) (62)
White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin (2005) (62)
Rheumatic heart disease in indigenous populations. (2010) (61)
Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy (2013) (61)
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction* (2009) (61)
Higher sensitivity troponin levels in the community: what do they mean and how will the diagnosis of myocardial infarction be made? (2010) (60)
Effect of aortic valve replacement on c-reactive protein in nonrheumatic aortic stenosis. (2003) (60)
Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. (1999) (60)
Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation. (2003) (59)
Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. (2006) (59)
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients (2014) (59)
Utility of cardiac biomarkers for the diagnosis of type V myocardial infarction after coronary artery bypass grafting: insights from serial cardiac MRI (2011) (59)
Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. (2013) (59)
The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. (2002) (59)
Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study (2013) (59)
Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study. (2009) (58)
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. (2008) (57)
Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. (1998) (57)
Changes in Lipoprotein‐Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Long‐term Intervention with Pravastatin in Ischemic Disease Study (2013) (57)
Time to Coronary Angiography and Outcomes Among Patients With High-Risk Non–ST-Segment–Elevation Acute Coronary Syndromes: Results From the SYNERGY Trial (2007) (57)
Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. (2008) (56)
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES (2019) (56)
Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). (2008) (56)
The All New Zealand Acute Coronary Syndrome Quality Improvement Programme: Implementation, Methodology and Cohorts (ANZACS-QI 9). (2016) (55)
Safety and efficacy of enoxaparin vs. unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes. who receive tirofiban and aspirin ☆ (2004) (55)
Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. (2003) (55)
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. (2003) (55)
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (2018) (55)
Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making. (2003) (55)
The effect of transcutaneous electrical nerve stimulation on coronary and systemic haemodynamics in syndrome X (1996) (54)
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. (2016) (54)
2007 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes 2006 (2008) (54)
Clinical implications of the Third Universal Definition of Myocardial Infarction (2013) (53)
Prediction of One-Year Survival in High-Risk Patients with Acute Coronary Syndromes: Results from the SYNERGY Trial (2008) (53)
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. (2004) (53)
Relation of Increased Arterial Blood Pressure to Mortality and Stroke in the Context of Contemporary Thrombolytic Therapy for Acute Myocardial Infarction (1996) (53)
Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. (2015) (53)
Systems of care: need for hub-and-spoke systems for both primary and systematic percutaneous coronary intervention after fibrinolysis. (2008) (52)
Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. (2011) (51)
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. (2010) (51)
Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial. (2019) (50)
Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. (2016) (50)
Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and stenosis severity. (1998) (50)
Sharing Data from Cardiovascular Clinical Trials--A Proposal. (2016) (50)
Persistent psychological distress and mortality in patients with stable coronary artery disease (2017) (50)
Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial. (2007) (50)
Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. (2013) (50)
Applying the open artery theory: use of predictive survival markers. (1998) (49)
Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. (2020) (49)
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). (2002) (48)
Diagnostic application of the universal definition of myocardial infarction in the intensive care unit (2008) (48)
Statin Use and Sex-Specific Stroke Outcomes in Patients With Vascular Disease (2006) (48)
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis (2019) (48)
Relationship of QRS duration at baseline and changes over 60 min after fibrinolysis to 30-day mortality with different locations of ST elevation myocardial infarction: results from the Hirulog and Early Reperfusion or Occlusion-2 trial (2008) (48)
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. (2006) (48)
The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? (2000) (48)
Redefining medical treatment in the management of unstable angina. (2011) (48)
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial (2018) (47)
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). (2009) (47)
The prognostic meaning of the full spectrum of aVR ST-segment changes in acute myocardial infarction. (2012) (46)
Diagnosis of MI after CABG with high-sensitivity troponin T and new ECG or echocardiogram changes: relationship with mortality and validation of the Universal Definition of MI (2013) (46)
Comparative case fatality analysis of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial: variation by country beyond predictive profile. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. (1993) (46)
Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. (2015) (46)
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial (2019) (46)
The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction. (2007) (46)
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. (2008) (46)
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. (2019) (45)
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. (2009) (45)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2019) (45)
Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience (2002) (45)
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome (2020) (45)
Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. (2012) (45)
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. (2006) (44)
Universal Definition of Myocardial Infarction 2007 (2012) (44)
Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. (2001) (44)
Initial Aspirin Dose and Outcome Among ST-Elevation Myocardial Infarction Patients Treated With Fibrinolytic Therapy (2008) (44)
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). (2014) (43)
STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. (2010) (43)
Tooth loss is independently associated with poor outcomes in stable coronary heart disease (2016) (43)
The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT‐2): A randomized trial design (2019) (43)
The evolving role of direct thrombin inhibitors in acute coronary syndromes. (2003) (43)
Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. (1993) (43)
International variation in the use of evidence-based medicines for acute coronary syndromes. (2003) (43)
Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial. (2019) (43)
Universal MI Definition Update for Cardiovascular Disease (2014) (42)
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. (2013) (42)
Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial (2016) (42)
Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial (2017) (42)
Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors (2015) (42)
Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study (2016) (42)
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries. (1999) (41)
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. (2013) (41)
Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure. (1985) (41)
Usefulness of the presenting electrocardiogram in predicting successful reperfusion with streptokinase in acute myocardial infarction. (1999) (41)
Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors? (2003) (41)
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). (2014) (41)
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. (2021) (40)
Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. (2020) (40)
Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. (2016) (40)
Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. (2011) (40)
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. (2010) (40)
Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. (2002) (40)
A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. (2008) (39)
Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. (2003) (39)
Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure). (2014) (39)
Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis. (2011) (39)
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials (2017) (38)
Selection of reperfusion therapy for individual patients with evolving myocardial infarction. (1997) (38)
Lipoprotein‐Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease (2016) (38)
Relationship between corrected TIMI frame counts at three weeks and late survival after myocardial infarction. (2000) (38)
Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: Impact of age (A Meta-Analysis of a Decade of Trials) (2006) (38)
Acute Coronary Syndrome patients in New Zealand receive less invasive management when admitted to hospitals without invasive facilities. (2004) (38)
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. (2002) (38)
Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study (2021) (38)
Long-Term Effects of Percutaneous Coronary Intervention of the Totally Occluded Infarct-Related Artery in the Subacute Phase After Myocardial Infarction (2011) (38)
A randomized trial evaluating the effects of change in dairy food consumption on cardio-metabolic risk factors (2014) (37)
Pathobiology of Troponin Elevations (2011) (37)
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). (2015) (37)
Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized Clinical Trials (2011) (37)
Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks. (1999) (37)
International variation in invasive care of the elderly with acute coronary syndromes. (2006) (37)
Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. (2004) (36)
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. (2008) (36)
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). (2003) (36)
Prognosis after recovery from myocardial infarction: the relative importance of cardiac dilatation and coronary stenoses. (1992) (36)
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. (1997) (36)
Antianginal efficacy of perhexiline maleate in patients refractory to beta-adrenoreceptor blockade. (1983) (36)
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. (2020) (35)
International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes. (2008) (35)
Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran. (2012) (35)
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. (2020) (35)
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. (2011) (35)
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. (2017) (34)
Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. (1999) (34)
Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. (2011) (34)
Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial (2011) (34)
Aspirin Use Post-Acute Coronary Syndromes: Intolerance, Bleeding and Discontinuation (2003) (34)
Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes (2017) (34)
Cholesterol‐lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost‐effective? (2002) (34)
Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. (1998) (34)
Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes (2018) (33)
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. (2016) (33)
A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial (2013) (33)
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non–ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years (2015) (33)
Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50 (2015) (33)
Relationship between initial white blood cell counts, stage of acute myocardial infarction evolution at presentation, and incidence of Thrombolysis In Myocardial Infarction-3 flow after streptokinase. (2003) (33)
Restrictive physiology in cardiogenic shock: observations from echocardiography. (2006) (33)
State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease. (2017) (33)
Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. (2010) (33)
Prognostic Value of Lead V1 ST Elevation During Acute Inferior Myocardial Infarction (2010) (32)
Long-Term Follow-Up of Gender-Specific Outcomes After Thrombolytic Therapy for Acute Myocardial Infarction from the GUSTO-I Trial (1997) (32)
Cardiovascular disease on a global scale: defining the path forward for research and practice. (2007) (32)
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. (2006) (32)
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. (2005) (32)
Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. (2001) (32)
Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. (1995) (32)
Patients admitted with an acute coronary syndrome (ACS) in New Zealand in 2007: results of a second comprehensive nationwide audit and a comparison with the first audit from 2002. (2010) (31)
After Correcting for Worse Baseline Characteristics, Women Treated With Thrombolytic Therapy for Acute Myocardial Infarction Have the Same Mortalit and Morbidit as Men Except for a Higher Incidence of Hemorrhagic Stroke (1993) (31)
Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction. (2003) (31)
Evolution of the definition of myocardial infarction: what are the implications of a new universal definition? (2008) (31)
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction. (2010) (31)
Early ST-segment recovery, infarct artery blood flow, and long-term outcome after acute myocardial infarction. (2002) (31)
Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy. (2011) (30)
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes (2019) (30)
Comparison of case fatality in smokers and non-smokers after acute cardiac event (1997) (30)
Things ain't what they used to be: impact of a new definition of myocardial infarction. (2002) (30)
Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. (2012) (30)
Expert Consensus Document. Third Universal Definition of Myocardial Infarction (2013) (30)
The management of acute coronary syndrome patients across New Zealand in 2012: results of a third comprehensive nationwide audit and observations of current interventional care. (2013) (30)
New Q waves on the presenting electrocardiogram independently predict increased cardiac mortality following a first ST-elevation myocardial infarction. (2000) (29)
Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1997) (29)
Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock. (2007) (29)
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol (2021) (29)
Factors affecting outcome after recovery from myocardial infarction. (1994) (29)
Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. (2010) (28)
First and recurrent ischaemic heart disease events continue to decline in New Zealand, 2005–2015 (2017) (28)
Angiographic frame counts 90 minutes after streptokinase predict left ventricular function at 48 hours following myocardial infarction (1999) (28)
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial (2010) (28)
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions (2016) (28)
Management of patients admitted with an Acute Coronary Syndrome in New Zealand: results of a comprehensive nationwide audit. (2004) (28)
Carvedilol: use in chronic heart failure (2007) (28)
Candesartan and heart failure: the allure of CHARM (2003) (27)
Usefulness of the presenting electrocardiogram in predicting myocardial salvage with thrombolytic therapy in patients with a first acute myocardial infarction. (2002) (27)
Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. (2020) (27)
The Prequel: Defining Prognostically Important Criteria in the Periprocedural PCI Troponin Saga (2012) (27)
Impact of surgical ventricular reconstruction on sphericity index in patients with ischaemic cardiomyopathy: follow‐up from the STICH trial (2015) (27)
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manag (2015) (27)
Predictors of stroke in patients with coronary heart disease in the LIPID study (1999) (26)
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials (2015) (26)
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. (2015) (26)
Comparison of the effects of streptokinase and tissue plasminogen activator on regional wall motion after first myocardial infarction: analysis by the centerline method with correction for area at risk. (1991) (26)
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). (2004) (26)
The impact of the coronary collateral circulation on outcomes in patients with acute coronary syndromes: results from the ACUITY trial (2013) (26)
The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. (2008) (26)
Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. (2014) (25)
Ruling-In Myocardial Injury and Ruling-Out Myocardial Infarction With the European Society of Cardiology 1-Hour Algorithm (2016) (25)
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX (2015) (25)
Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. (2016) (25)
A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement. (2002) (25)
Addition of nifedipine to maximal beta-blocker-nitrate therapy: effects on exercise capacity and global left ventricular performance at rest and during exercise. (1985) (25)
Effects of early captopril administration after thrombolysis on regional wall motion in relation to infarct artery blood flow. (1999) (25)
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. (2008) (25)
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. (2004) (25)
Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. (2018) (24)
Avatar of the universal definition of periprocedural myocardial infarction. (2013) (24)
Variation in and prognostic importance of troponin T measured using a high-sensitivity assay in clinically stable haemodialysis patients (2012) (24)
Comparison of four risk scores for contemporary isolated coronary artery bypass grafting. (2014) (24)
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. (2010) (24)
Efficacy of a novel P-selectin antagonist, rPSGL-Ig for reperfusion therapy in acute myocardial infarction: The RAPSODY trial (2003) (24)
Whole blood sequencing reveals circulating microRNA associations with high-risk traits in non-ST-segment elevation acute coronary syndrome. (2017) (24)
Unmet therapeutic needs in the management of acute ischemia. (1997) (23)
A Review of its Pharmacological Properties and Clinical Efficacy in the Management of Acute Myocardial Infarction (1996) (23)
Should all occluded infarct-related arteries be opened? (1997) (23)
Noninvasive, medical management for non-ST-elevation acute coronary syndromes. (2008) (23)
Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. (2007) (23)
Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. (2017) (23)
Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study. (2006) (23)
Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups (2006) (23)
Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis. (2012) (23)
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. (2006) (23)
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. (2006) (22)
The TETAMI Trial: The Safety and Efficacy of Subcutaneous Enoxaparin versus Intravenous Unfractionated Heparin and of Tirofiban versus Placebo in the Treatment of Acute Myocardial Infarction for Patients Not Thrombolyzed: Methods and Design (2000) (22)
Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Substudy (2010) (22)
Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. (2002) (22)
Addition of nifedipine to maximal nitrate and beta-adrenoreceptor blocker therapy in coronary artery disease. (1985) (22)
Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction (2007) (21)
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non–ST-Segment–Elevation Acute Coronary Syndromes Clinical Trials (2016) (21)
Will new higher-precision troponins lead to clarity or confusion? (2008) (21)
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial (2020) (21)
Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial. (2013) (21)
Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial. (1998) (21)
Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict. (2008) (21)
Magnitude of Troponin Elevation and Long-Term Clinical Outcomes in Acute Coronary Syndrome Patients Treated With and Without Revascularization (2015) (21)
A score predicts failure of reperfusion after fibrinolytic therapy for acute myocardial infarction. (2003) (21)
The Role of Lipoprotein-Associated Phospholipase A2 as a Marker and Potential Therapeutic Target in Atherosclerosis (2011) (21)
Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2017) (20)
Electrocardiographic findings in cardiogenic shock, risk prediction, and the effects of emergency revascularization: results from the SHOCK trial. (2004) (20)
Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. (2003) (20)
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). (2014) (20)
Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease (2019) (20)
The impact of a national COVID-19 lockdown on acute coronary syndrome hospitalisations in New Zealand (ANZACS-QI 55) (2020) (20)
Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS (2018) (20)
Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. (2008) (20)
High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality. (2022) (20)
Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER (2014) (20)
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. (2005) (20)
Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial. (2015) (20)
Lp(a) and Cardiovascular Outcomes: an Analysis from the ODYSSEY OUTCOMES Trial (2018) (20)
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. (2016) (20)
Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. (2013) (20)
All-Cause Mortality Following an Acute Coronary Syndrome: 12-Year Follow-Up of the Comprehensive 2002 New Zealand Acute Coronary Syndrome Audit. (2017) (19)
Cardiogenic shock: predictors of outcome based on right and left ventricular size and function at presentation (2005) (19)
Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50 (2016) (19)
Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. (2014) (19)
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome (2017) (19)
Mapping the antigenic regions of streptokinase in humans before and after streptokinase therapy. (1995) (19)
Prediction of Residual Risk by Ceramide‐Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy (2020) (19)
High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. (2017) (19)
Is our method of obtaining consent appropriate for randomised controlled trials in acute myocardial infarction? (1997) (19)
Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarction. (2015) (19)
Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes (2015) (19)
Alirocumab and Cardiovascular Outcomes in Patients with Acute Coronary Syndrome (ACS) and Diabetes—Prespecified Analyses of ODYSSEY OUTCOMES (2018) (18)
Exercise responses before and after long-term treatment with oral milrinone in patients with severe heart failure. (1986) (18)
Implications of the universal definition of myocardial infarction (2008) (18)
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). (2014) (18)
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). (2015) (18)
Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention. (2009) (18)
"Rescue" thrombolysis with intracoronary tissue plasminogen activator for failed intravenous thrombolysis with streptokinase for acute myocardial infarction. (1995) (18)
The forgotten lead: does aVR ST-deviation add insight into the outcomes of ST-elevation myocardial infarction patients? (2013) (18)
Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion (2002) (18)
ACS patients in New Zealand experience significant delays to access cardiac investigations and revascularisation treatment especially when admitted to non-interventional centres: results of the second comprehensive national audit of ACS patients. (2010) (18)
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. (2014) (18)
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. (2020) (18)
Selecting a Thrombol Ytic Agent (1995) (17)
Relation of initial platelet counts to Thrombolysis In Myocardial Infarction-3 flow rates at 90 minutes after commencing fibrinolytic therapy in patients with acute myocardial infarction. (2002) (17)
Patients with circumflex occlusions miss out on reperfusion: how to recognize and manage them (2012) (17)
Thrombolytic therapy and equivalence trials. (1998) (17)
Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes (2010) (17)
Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial (2017) (17)
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial (2010) (17)
Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. (2016) (17)
Design of a trial evaluating myocardial cell protection with cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger: the Guard During Ischemia Against Necrosis (GUARDIAN) trial (2000) (17)
Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome (2014) (17)
Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes. (2006) (16)
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) (2018) (16)
New antiplatelet agents. (1998) (16)
Results of percutaneous coronary angioplasty in patients <40 years of age. (1998) (16)
Trans-fatty acids in New Zealand patients with coronary artery disease (2011) (16)
The declining prevalence of ST elevation myocardial infarction in patients presenting with acute coronary syndromes (2005) (16)
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention (2016) (16)
Relation of thrombolysis during acute myocardial infarction to left ventricular function and mortality. (1990) (16)
Clinical Trials of Direct Thrombin Inhibitors in Acute Ischaemic Syndromes (1997) (16)
Effects of streptokinase in patients presenting within 6 hours of prolonged chest pain with ST segment depression. (1995) (16)
Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. (2005) (15)
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol (2021) (15)
Lifting the smoke-screen: the enigma of better outcome in smokers after myocardial infarction. (1995) (15)
Cholesterol-lowering therapy is more cost-effective for older than younger patients: results from the LIPID study (2001) (15)
Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. (2013) (15)
Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. (2021) (15)
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. (2014) (15)
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial (2012) (15)
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial (2015) (15)
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. (2020) (15)
Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction model. (2017) (15)
Lack of relationship between obesity and mortality or morbidity after coronary artery bypass grafting. (2013) (15)
Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. (2010) (15)
Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial (2009) (15)
Under-use of secondary prevention medication in acute coronary syndrome patients treated with in-hospital coronary artery bypass graft surgery. (2011) (15)
Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. (2005) (15)
Variation in blood levels of inflammatory markers related and unrelated to smoking cessation in women. (2007) (15)
Endothelium-dependent dilation of the coronary arteries in syndrome X: effects of the cold pressor test. (1997) (15)
Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study. (2014) (15)
Newer antiplatelet agents in acute coronary syndromes. (1999) (15)
Overview and determinants of cardiovascular disease in indigenous populations. (2010) (15)
The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. (2009) (14)
Comparison of effects of thrombolytic therapy on left ventricular function in patients over with those under 60 years of age. (1991) (14)
The HERO-2 ECG sub-studies in patients with ST elevation myocardial infarction: implications for clinical practice. (2013) (14)
Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions (2002) (14)
Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention. (2011) (14)
Comparison of nifedipine and isosorbide dinitrate when added to maximal propranolol therapy in stable angina pectoris. (1987) (14)
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. (2006) (14)
Treatment of primary hypercholesterolaemia with simvastatin New Zealand multicentre evaluation (1991) (14)
Drug Insight: statin use in the elderly (2006) (14)
The relationship between meteorological conditions and index acute coronary events in a global clinical trial. (2013) (14)
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib (2017) (13)
Optimal treatment of patients with acute coronary syndromes and non-ST-elevation myocardial infarction. (1999) (13)
Issues regarding the use of heparin following streptokinase therapy (2005) (13)
Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS (2019) (13)
Maori have worse outcomes after coronary artery bypass grafting than Europeans in New Zealand. (2013) (13)
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. (2016) (13)
Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics (2009) (13)
One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. (1996) (13)
Coronary disease in indigenous populations: summary from the CSANZ indigenous Cardiovascular Health Conference. (2010) (13)
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy (2016) (13)
Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study. (1998) (13)
Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. (2008) (13)
Lessons Learned From a Clinical Trial (2004) (13)
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST‐elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial (2018) (13)
Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements (2020) (12)
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). (2017) (12)
Non-invasive diagnosis of arterial patency after thrombolytic treatment and its relation to prognosis. (1993) (12)
Cardiovascular Outcomes With Alirocumab After Acute Coronary Syndrome: Results of the Odyssey Outcomes Trial (2018) (12)
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. (2013) (12)
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial (2018) (12)
Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. (2018) (12)
Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. (2016) (12)
We must use the knowledge that we have to treat patients with acute coronary syndromes. (2004) (12)
Improving cardiovascular care for indigenous populations. (2010) (12)
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial (2019) (12)
Comparative safety of thrombolytic agents. (1991) (12)
Higher mortality in women undergoing coronary artery bypass grafting. (2013) (12)
887-2 Cardiogenic shock in patients with preserved left ventricular systolic function: Characteristics and insight into mechanisms (2004) (11)
One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial. (2010) (11)
Implications of the new definition of myocardial infarction (2005) (11)
Has the mortality rate from acute myocardial infarction fallen substantially in recent years? (2002) (11)
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial (2011) (11)
Risk stratification and treatment benefits in patients with non-ST-elevation acute coronary syndromes. (2002) (11)
Risk stratification of patients with right ventricular infarction: is there a need for a specific risk score? (2002) (11)
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. (2021) (11)
PHARMAC and the statin debacle. (2006) (11)
Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. (2017) (11)
Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy. (2008) (11)
The LIPID trial impact of lipid lowering therapy with pravastatin on the risk of stroke (1998) (11)
Prevention by nifedipine of cold pressor-induced decrease in left ventricular ejection fraction. (1983) (11)
Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome (2009) (11)
Comparative Tolerability Profiles of Thrombolytic Agents (1993) (11)
Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. (2018) (11)
Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. (2013) (11)
The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial. (2005) (11)
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial (2018) (11)
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. (1999) (11)
Strategies to minimize bleeding complications of percutaneous coronary intervention (2009) (11)
Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin (2002) (11)
Can streptokinase produce beneficial effects additional to coronary recanalization? Quantitative microvascular analysis of critically injured reperfused myocardium. (2000) (11)
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. (2019) (11)
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment (2021) (11)
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study (2017) (11)
Association of angiographically detected coronary artery disease with low levels of high-density lipoprotein cholesterol and systemic hypertension. (1993) (11)
Value of community-derived risk models for stratifying patients with non-ST elevation acute coronary syndromes. (2005) (11)
30-day mortality after percutaneous coronary intervention in New Zealand public hospitals (ANZACS-QI 18). (2017) (10)
Aspirin does not improve early arterial patency after streptokinase treatment for acute myocardial infarction. (1993) (10)
Towards a new order in cardiovascular medicine: re-engineering through global collaboration. (2010) (10)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (10)
Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled trial with angiographic and clinical follow-up after myocardial infarction. (2007) (10)
Lack of association between baseline plasma homocysteine concentrations and restenosis rates after a first elective percutaneous coronary intervention without stenting (2004) (10)
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial (2022) (10)
Association Between Very Low Levels of High‐Density Lipoprotein Cholesterol and Long‐term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial (2016) (10)
Medical treatment for acute coronary syndromes. (2000) (10)
Further evidence that antithrombotic therapy is beneficial with streptokinase: improved early ST resolution and late patency with enoxaparin. (2002) (10)
Postmenopausal hormone use in women with acute coronary syndromes. (2004) (10)
The corrected TIMI frame count. The new gold standard? (1998) (10)
Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery (2015) (10)
Comparison of the management and in‐hospital outcomes of acute coronary syndrome patients in Australia and New Zealand: results from the binational SNAPSHOT acute coronary syndrome 2012 audit (2015) (10)
Moving cardiology to the front of the hospital (2000) (10)
High-sensitivity troponin level pre-catheterization predicts adverse cardiovascular outcomes after primary angioplasty for ST-elevation myocardial infarction (2014) (10)
Debate: Should the elderly receive thrombolytic therapy or primary angioplasty? (2000) (10)
Outcome of Thrombolytic Therapy in Relation to Hospital Size and Invasive Cardiac Services (1994) (10)
Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. (2010) (10)
Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization (2017) (9)
Relationship Between Peak Troponin Values and Long‐Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes (2017) (9)
Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial (2016) (9)
Smoking and acute myocardial infarction. (1993) (9)
Corrected TIMI frame counts correlate with stenosis severity and infarct zone wall motion after thrombolytic therapy. (2001) (9)
Acute reperfusion for ST-elevation myocardial infarction in New Zealand (2015-2017): patient and system delay (ANZACS-QI 29). (2019) (9)
Selecting a thrombolytic agent. (1995) (9)
Resolution of ST depression after fibrinolysis can be more important than resolution of ST elevation for many patients with inferior STEMIs. (2015) (9)
TRADEOFF BETWEEN MYOCARDIAL INFARCTION VERSUS BLEEDING TYPES ON MORTALITY AFTER ACUTE CORONARY SYNDROME: LESSONS FROM THE THROMBIN RECEPTOR ANTAGONIST FOR CLINICAL EVENT REDUCTION IN ACUTE CORONARY SYNDROME (TRACER) RANDOMIZED TRIAL (2016) (9)
High‐Sensitivity Cardiac Troponin T in Stable Patients Undergoing Pharmacological Stress Testing (2015) (9)
Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis). (2001) (9)
Relationship of QRS Duration at Baseline and Changes Over 60 min After Fibrinolysis to 30-Day Mortality with Different Locations of ST Elevation Myocardial Infarction: Results from the HERO-2 Trial (2007) (9)
Prognostic performance of kinetic changes of high-sensitivity troponin T in acute coronary syndrome and in patients with increased troponin without acute coronary syndrome. (2014) (9)
The Efficacy and Safety of Cangrelor in Women Versus Men During PCI: Insights From the CHAMPION PHOENIX Trial (2016) (8)
Comparison of tissue plasminogen activator and streptokinase in the management of acute myocardial infarction. (1989) (8)
Risk Markers of Incident Atrial Fibrillation in Patients with Coronary Heart Disease. (2021) (8)
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. (2018) (8)
The role of natriuretic peptides in patients with chronic complex (mixed or multiple) heart valve disease. (2010) (8)
Magnetic resonance imaging and troponin elevation following percutaneous coronary intervention: new insights into myocyte necrosis and scar formation. (2010) (8)
Consensus statement on the use of high sensitivity cardiac troponins : consensus statement (2012) (8)
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. (2022) (8)
Interventional Cardiology Long-Term Effects of Percutaneous Coronary Intervention of the Totally Occluded Infarct-Related Artery in the Subacute Phase After Myocardial Infarction (2011) (8)
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience (2018) (8)
Effects of thrombolytic therapy on left ventricular function and the importance of long-term patency of the infarct-related artery. (1995) (8)
Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial). (2014) (8)
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention (2017) (8)
Thrombolytic Therapy in the Elderly (1996) (8)
Resolution of ST-segment elevation 90 minutes after thrombolysis for acute myocardial infarction predicts outcome: a GUSTO-III substudy (1998) (8)
Editorial: do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer? (2011) (8)
Coronary artery bypass graft surgery in New Zealand's Auckland region: a comparison between the clinical priority assessment criteria score and the actual clinical priority assigned. (2006) (8)
Associations between ST depression, four year mortality, and in-hospital revascularisation in unselected patients with non-ST elevation acute coronary syndromes (2003) (8)
A prospective, randomized trial of bivaliruclin in acute coronary syndromes: One year results from the ACUITY Trial (2007) (8)
Improved left ventricular function and early survival with intravenous streptokinase a double blind trial (1986) (8)
Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease – A STABILITY Substudy (2022) (8)
Cardiogenic shock from left ventricular dysfunction complicating an acute ST-elevation myocardial infarction. (2009) (8)
Inadequate control of lipid levels in patients with a previous myocardial infarction. (1998) (8)
A Randomised Trial Evaluating the Effects of Change in Dairy Food Consumption on Cardio-Metabolic Risk Factors (2013) (7)
Public sensationalism and clinical trials: how to address the challenges of science? (2010) (7)
Non-invasive diagnosis of infarct artery patency after acute myocardial infarction by use of serial plasma troponin T concentrations: importance of measurement of peak levels. (1996) (7)
Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion. (2002) (7)
861-2 Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin, and an early conservation initial management strategy: Results from the A phase of the A to Z trial (2004) (7)
Survival After Invasive or Conservative Management of Stable Coronary Disease (2022) (7)
Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2. (2006) (7)
Adjunctive Use of Direct Thrombin Inhibitors in Patients Receiving Fibrinolytic Therapy for Acute Myocardial Infarction (2004) (7)
Relationship of Outcomes to Treatment with Lamifiban in Patients Undergoing PTCA: Analysis of PARAGON A (1997) (7)
Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM Trial. (2016) (7)
Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. (2021) (7)
Direct Antithrombins (2007) (7)
Relation of pathologic Q waves at presentation and time to streptokinase therapy with early changes in infarct-related artery flow and ventricular wall motion. (2001) (7)
Myocardial infarction: why can't we get the diagnosis right? (2003) (7)
Frequency of recurrent ST-elevation myocardial infarction after fibrinolytic therapy in a different territory as a manifestation of multiple unstable coronary arterial plaques. (2006) (7)
Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease. (1990) (7)
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar (2016) (7)
Prospective evaluation of a chest pain pathway at Green Lane Hospital. (2002) (7)
Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX (2017) (7)
Lipoprotein-Associated Phospholipase A 2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease (2016) (7)
Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization (2020) (6)
Abstract 19049: Net Clinical Benefit of Vorapaxar in NSTE ACS: Role of Ischemic and Bleeding Risk Stratification (2012) (6)
One-year survival following early revascularization for cardiogenic shock (SCHOCK trial). (2001) (6)
Late diverging event curves for survival following IIb/IIIa antagonism in patients with unstable angina: PARAGON study 1-year follow-up (1998) (6)
Impact of enoxaparin on thrombus formation, coronary blood flow, and myocardial perfusion after early invasive treatment during acute coronary syndrome: Results from the SYNERGY library (2006) (6)
Remodelling of the heart after myocardial infarction. (1992) (6)
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. (2019) (6)
Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease (2018) (6)
New ST-depression: an under-recognized high-risk category of ‘complete’ ST-resolution after reperfusion therapy (2012) (6)
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab (2022) (6)
Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. (2019) (6)
LEFT VENTRICULAR FUNCTION FOLLOWING THROMBOLYTIC THERAPY FOR MYOCARDIAL INFARCTION (1995) (6)
Recommendations arising from the inaugural CSANZ Conference on Indigenous Cardiovascular Health. (2010) (6)
ST deviations and serial changes after reperfusion therapy in patients with inferior STEMIs: Relationship between inferior leads, medial chest leads and lateral leads. (2015) (6)
PHARMAC and lack of funding for clopidogrel. (2005) (6)
Outcome of thrombolytic therapy in relation to hospital size and invasive cardiac services. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. (1994) (6)
Abstract 13482: Ischemic Cardiac Outcomes in Patients with AF Treated with Vitamin K Antagonism or Factor Xa Inhibition: Results from the ROCKET AF Trial (2011) (6)
The Cardiac Society Inaugural Cardiovascular Health Conference: conference findings and ways forward. (2010) (6)
Use of creatine kinase isoforms for diagnosis of infarct artery patency after thrombolytic therapy with streptokinase (1993) (6)
Diagnosis of myocardial infarction and prognostic utility of high-sensitivity troponin T after isolated aortic valve replacement ☆ ☆☆ ★ (2016) (6)
Self‐Reported Health and Outcomes in Patients With Stable Coronary Heart Disease (2017) (6)
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. (2016) (6)
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. (2018) (5)
Sex And Prognostic Significance of Self-Reported Frailty in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial. (2019) (5)
Recognising “painless” heart attacks (2002) (5)
Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. (2016) (5)
A decade of improvement in the management of New Zealand ST-elevation myocardial infarction (STEMI) patients: results from the New Zealand Acute Coronary Syndrome (ACS) Audit Group national audits of 2002, 2007 and 2012. (2017) (5)
Utilisation and maintenance of high-intensity statins following acute coronary syndrome and coronary angiography: opportunities to improve care (ANZACS-QI 26). (2020) (5)
Increased myocardial ischemia after food is not explained by endothelial dysfunction. (2002) (5)
An overview of the patency and stroke rates following thrombolysis with streptokinase, alteplase, and anistreplase used to treat an acute myocardial infarction. (1993) (5)
Risk Factors for In-hospital Nonhemorrhagic Stroke in Patients With Acute Myocardial Infarction Treated With Thrombolysis: Results from GUSTO-I : Results From Gusto-I (1998) (5)
International differences in patients, care, and outcomes associated with acute myocardial infarction: the hero-2 trial (2002) (5)
Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. (2019) (5)
"Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings. (2016) (5)
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial (2016) (5)
Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome (2019) (5)
Improved efficacy and less bleeding: further evidence of a unique uncoupling of benefit and risk with bivalirudin. (2002) (5)
Abstract 9150: Re-Elevation of Troponin Following Percutaneous Coronary Intervention Significantly Predicts 1-Year Mortality in Patients with High-risk Non-ST-Segment Elevation Acute Coronary Syndromes (2011) (5)
Systems of care: need for hub and spoke systems of care for patients with myocardial infarction. A call for action. (2010) (5)
Abstract 18595: Efficacy of Vorapaxar is not Modified by Thienopyridine Therapy: Results from TRA 2°P-TIMI 50 Trial (2012) (5)
Heart failure and/or left ventricular systolic dysfunction complicating myocardial infarction is common and accounts for the majority of in-hospital myocardial infarction mortality: Results of the VALIANT registry (2003) (5)
With the Society of Geriatric Cardiology In Collaboration American Heart Association Council on Clinical Cardiology: Infarction: A Scientific Statement for Healthcare Professionals From the Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial (2007) (5)
Targeting Therapy to the Fibrin-Mediated Pathophysiology of Acute Coronary Syndrome (2014) (5)
Clarifying the Proper Definitions for Type 2 Myocardial Infarction. (2018) (5)
Availability of troponin testing for cardiac patients in New Zealand 2002 to 2011: implications for patient care. (2012) (5)
Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. (2016) (5)
A case of cardiogenic shock caused by capecitabine treatment (2008) (5)
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial (2016) (5)
Cardiogenic shock: a more aggressive approach is now warranted. (2000) (5)
755-5 Risk Factors for Stroke Following Thrombolytic Therapy: Case-Control Study from the GUSTO Trial (1995) (5)
IMPACT OF SURGICAL VENTRICULAR RECONSTRUCTION ON SPHERICITY INDEX IN PATIENTS WITH ISCHEMIC CARDIOMYOPATHY: FOLLOW-UP FROM STICH TRIAL (2014) (5)
Antithrombotic therapy in ST-segment elevation myocardial infarction (2011) (5)
The ODYSSEY OUTCOMES Trial (2019) (5)
Discharge timing and outcomes after uncomplicated non–ST‐segment elevation acute myocardial infarction (2018) (5)
Acute myocardial infarction: Fibrinolytic therapy (2004) (5)
Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. (2021) (5)
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study (2018) (4)
Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial (2018) (4)
Prognostic significance of diabetes mellitus in patients with acute myocardial infarction. Implications for thrombolytic therapy (1993) (4)
Practising what is preached: the MINAP study (2004) (4)
Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals (2022) (4)
The Impact of Postrandomization Crossover of Therapy in Acute Coronary Syndromes Care (2011) (4)
Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb. (2008) (4)
Meta-Analysis of Bleeding Scores Performance for Acute Coronary Syndrome. (2020) (4)
Is Heparin of Value in the Management of Acute Myocardial Infarction? (1997) (4)
Rivaroxaban for the treatment of acute coronary syndromes (2013) (4)
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. (2020) (4)
Natriuretic peptides are elevated in aortic regurgitation but correlate poorly with disease severity (2003) (4)
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. (2002) (4)
Fibrinolysis for Acute Myocardial Infarction in the Elderly Patient: Is it Effective or Too Dangerous? (1998) (4)
ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis (2007) (4)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (4)
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil (2010) (4)
OUTCOMES OF PATIENTS WITH ACUTE CORONARY SYNDROMES AND PRIOR CORONARY ARTERY BYPASS GRAFTING: ANALYSIS FROM THE ACUITY TRIAL (2010) (4)
The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX (2019) (4)
Prosthetic heart valves and pregnancy. (2003) (4)
Cardiac death should be the primary endpoint for revascularization trials and meta-analyses. (2021) (4)
Myocardial infarction following sclerotherapy in a patient with a patent foramen ovale. (2012) (4)
Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies (2022) (4)
Drug Interactions with Cardiac Glycosides: Evaluation of a Possible Digoxin‐Ethmozine Pharmacokinetic Interaction (1987) (4)
Smoking: back to the future - again? (2000) (4)
CANGRELOR IN ELDERLY PATIENTS UNDERGOING PCI: FINDINGS FROM CHAMPION-PHOENIX (2015) (4)
Policy Development Plan for the Concept of Family Presence in the Johns Hopkins Department of Radiology: A Patient Safety Initiative (2006) (4)
International differences: selection, noise, or real? (2000) (4)
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. (2005) (4)
THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL (2015) (3)
International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. (2019) (3)
The genomics of heart failure: design and rationale of the HERMES consortium (2021) (3)
Type 2 MI and Myocardial Injury in the Era of High-sensitivity Troponin (2022) (3)
THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL INFARCTION—ROUND 2 (1988) (3)
Complex valve disease: pre-surgical functional capacity evaluation using peak oxygen consumption. (2009) (3)
A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort. (2010) (3)
Republished: Clinical implications of the Third Universal Definition of Myocardial Infarction (2014) (3)
Letter by Mehran et al regarding article, "Bleeding academic research consortium consensus report: the food and drug administration perspective". (2012) (3)
Darapladib and its potential for plaque stabilization and prevention of cardiac events (2010) (3)
Left ventricular function as an end-point of thrombolytic therapy. (1990) (3)
ISCHEMIC EVENTS OCCUR EARLY IN PATIENTS UNDERGOING PCI AND ARE REDUCED WITH CANGRELOR: FINDINGS FROM CHAMPION PHOENIX (2017) (3)
Combining IIb/IIIa Inhibition and Heparin for Acute Coronary Syndromes: Evidence of a Gradient for Bleeding Hazard from the PARAGON Randomized Factorially Designed Trial (1997) (3)
High-sensitivity CRP does not independently predict subsequent events in stable CHD patients in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study (2012) (3)
Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES. (2020) (3)
Abstract 2811: Predictors of Outcome and the Lack of Effect of PCI Across the Risk Strata in Patients With Persistent Total Occlusion After Myocardial Infarction: Results from the Occluded Artery Trial (OAT) (2007) (3)
IMPACT OF SMOKING STATUS ON CLINICAL OUTCOMES WITH PRASUGREL VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES MANAGED WITHOUT revascularization: INSIGHTS FROM THE TRILOGY ACS TRIAL (2013) (3)
Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy (2018) (3)
Pravastatin therapy and the risk of stroke: results from the LIPID study (2000) (3)
Thrombolytic therapy in acute myocardial infarction. (1994) (3)
Morphine and Clinical Outcomes in Patients with ST segment elevation Myocardial Infarction Treated with Fibrinolytic and Antiplatelet Therapy: Insights from the TREAT Trial. (2022) (3)
EFFECTS OF GLYCOPROTEIN IIB/IIIA INHIBITORS IN COMBINATION WITH VORAPAXAR, A PLATELET THROMBIN-RECEPTOR ANTAGONIST, AMONG PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE TRACER TRIAL (2013) (3)
Prescribing Performance Post-Acute Coronary Syndrome Using a Composite Medication Indicator: ANZACS-QI 24. (2020) (3)
Abstract 10045: A Novel Approach to Define Type 4a Myocardial Infarction in Acute Coronary Syndrome Patients Undergoing Early Invasive Management: Insights From the CHAMPION PLATFORM Trial (2011) (3)
Hirudin and Hirulog. (1993) (3)
Management of non ST-elevation acute coronary syndrome patients in New Zealand: a longitudinal analysis. Results from the New Zealand Acute Coronary Syndrome national audits of 2002, 2007 and 2012. (2016) (3)
Thrombin Hypothesis: The TIMI 9B and GUSTO IIB Trials Have Successfully Disproven/Proven the Thrombin Hypothesis (2004) (3)
Comparison of aspirin with a thromboxane antagonist for patients with prolonged chest pain and ST segment depression. (1996) (3)
Unstable Angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS (1999) (3)
Hirudin Significantly Reduces Ischemic Events Following Coronary Intervention for Acute Coronary Syndromes (2000) (3)
TCT-79 Efficacy of Cangrelor in Lesions with High-Risk and Low-Risk Angiographic Characteristics: The CHAMPION PHOENIX trial (2015) (3)
High flow oxygen and risk of mortality in patients with a suspected acute coronary syndrome: pragmatic, cluster randomised, crossover trial (2021) (3)
Clinically Important Improvements in Risk Assessment by Adding High-Sensitivity Troponin Level to Cholesterol Guidelines. (2020) (3)
Biomarkers in Acute Ischemic Heart Disease (2011) (3)
Dithering over the treatment of diabetics with acute myocardial infarction. (2000) (3)
Effects of Dietary Factors on Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) (2011) (3)
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. (2022) (3)
Adjunctive antithrombotic therapy with primary percutaneous coronary intervention in ST elevation myocardial infarction: ATOLL in perspective. (2019) (3)
Reduced synthesis of tissue plasminogen activator by vascular endothelium during acute myocardial infarction. (1992) (3)
Relationship of Platelet Reactivity With Bleeding Outcomes During Long‐Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non‐ST‐Segment Elevation Acute Coronary Syndromes (2016) (3)
Impact of nonculprit vessel myocardial perfusion on outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes: analysis from the ACUITY trial (Acute Catheterization and Urgent Intervention Triage Strategy). (2014) (3)
Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome. (2009) (3)
Reperfusion injury – a reply to Keith Fox (1992) (3)
Changes in Lp-PLA2 activity in secondary prevention Ppredict coronary events and treatment effect by Pravastatin in the long-term intervention with Pravastatin in ischaemic disease (LIPID) trial (2011) (2)
Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutancous coronary intervention: One year results from the randomized ACUITY trial (2007) (2)
Abstract 18856: Relationships Between ‘Mediterranean’ and ‘Western’ Dietary Patterns and Major Cardiovascular Events in Patients With Stable Coronary Heart Disease in the STABILITY Study (2014) (2)
The effects of streptokinase and tissue plasminogen activator on left ventricular function. (1990) (2)
External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation (2015) (2)
Facilitated percutaneous coronary intervention: Is this strategy ready for implementation? (2005) (2)
Abstract 2996: The Relationship of Heart Rate in the Early Post Myocardial Infarction Period and Long Term Outcome: Results From the VALsartan in Acute Myocardial iNfarcTion (VALIANT) Trial (2009) (2)
Advances in Acute Coronary Syndrome Management (2012) (2)
Compliance of balloon material does not effect angiographic dissection rate. Results from the CRAC(Compliant Related Acute Complication) study (1996) (2)
P858Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial (2017) (2)
Myocardial Infarction Mortality - Where Do We Go Now? (2007) (2)
Blinded adjudication of reinfarction following fibrinolysis: Data from the HERO-2 trial (2003) (2)
Antithrombin Agents as Adjuncts to Thrombolytic Therapy (1999) (2)
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients (2016) (2)
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial (2013) (2)
Abstract 16636: Left Ventricular Function and Remodeling Early After Coronary Artery Bypass Grafting Compared With Medical Therapy: Results From the Surgical Treatment for Ischemic Heart Failure (STICH)Trial (2014) (2)
Pre infarct angina pectoris predicts worse outcome in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gathered in the International TPA/SK Study (1991) (2)
The Impact of a National COVID-19 Lockdown on Acute Coronary Syndrome Hospitalisations in New Zealand: an ANZACS-QI study (2021) (2)
Abstract 2650: Safety and Efficacy of Crossover from Enoxaparin or Unfractionated Heparin to Bivalirudin: Results from ACUITY (2006) (2)
We should cap the health budget and spend more money on housing and food: NO. (2012) (2)
Higher aPTTs associated with worse outcomes after thrombolytic therapy with reduced-dose heparin: results from Assent-2 (2000) (2)
ALIROCUMAB AND CARDIOVASCULAR OUTCOMES IN WOMEN AFTER AN ACUTE CORONARY SYNDROME: AN ODYSSEY OUTCOMES TRIAL ANALYSIS (2020) (2)
Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction. (2014) (2)
Occluded infarct-related arteries and clinical events. (2000) (2)
Prasugrel, Māori, and personalised medicine in New Zealand. (2010) (2)
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial (2017) (2)
Does infection have a role in the pathogenesis of coronary artery disease? (2000) (2)
USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA (2017) (2)
Alirocumab after acute coronary syndrome in patients with a history of heart failure (2021) (2)
Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Peripheral Artery Disease : Results From TRACER (2013) (2)
Remodeling after myocardial infarction: An opportunity for early intervention (1997) (2)
Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). (2018) (2)
Lowering Cholesterol Levels in Patients with Coronary Heart-Disease - the 4s Trial Showed That Lowering High Cholesterol Levels Improves Survival in Patients with Coronary Heart-Disease - Do the Benefits Extend to Those with Average Cholesterol Levels (1995) (2)
EXERCISE CAPACITY AND MORTALITY IN PATIENTS WITH ISCHEMIC LEFT VENTRICULAR DYSFUNCTION RANDOMIZED TO CORONARY ARTERY BYPASS SURGERY OR MEDICAL THERAPY: AN ANALYSIS FROM THE SURGICAL TREATMENT FOR ISCHEMIC HEART FAILURE TRIAL (2014) (2)
Ef ﬁ cacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention The CHAMPION PHOENIX (2)
CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS : Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial (2013) (2)
Diabetes doubles the risk of death among patients presenting with acute coronary syndromes: insights from SYMPHONY, a large international trial (2001) (2)
Reducing the lifetime cardiovascular risk of New Zealanders. (2007) (2)
Missed opportunities for better health outcomes in New Zealand. (2004) (2)
Comparison of late results of percutaneous coronary intervention among stable patients ≤65 versus >65 years of age with an occluded infarct related artery (from the Occluded Artery Trial). (2012) (2)
Heart failure: to digitalise or not? The view against. (1992) (2)
TOOTH LOSS IS HIGHLY PREVALENT AND ASSOCIATED WITH CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH CHRONIC CORONARY HEART DISEASE IN THE GLOBAL STABILITY TRIAL (2013) (2)
Abstract 18805: Vorapaxar, A Platelet Thrombin-Receptor Antagonist, in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from the TRACER Trial (2012) (2)
Post-operative aspartate aminotransferase levels independently predict mortality after isolated coronary artery bypass grafting (2015) (2)
Direct thrombin inhibitors as adjuncts to thrombolytic therapy (1999) (2)
P1226Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES (2019) (2)
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. (2022) (2)
Simvastatin and atorvastatin have different effects at high doses on high density lipoprotein cholesterol and apolipoprotein A-I (1999) (2)
Hirudin Reduces Death and Myocardial (Re)infarction at 6 Months: Follow-up Results of the GUSTO IIb Trial (1998) (2)
Deconstructing the Paradox of Smoking and Improved Short-Term Cardiovascular Outcomes After Myocardial Infarction. (2020) (2)
Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. (2013) (2)
Optimal dosing of a glycoprotein IIb/IIIa antagonist with simplified renal-based algorithm: pharmacodynamic and clinical findings from PARAGON B (2001) (2)
Thrombolytic therapy for acute myocardial infarction in the elderly (2000) (2)
How Can You Have a Myocardial Infarction Without Significant Coronary Artery Disease? (2018) (2)
Thrombolysis: an effective therapy in acute coronary thrombosis. (1986) (2)
GALECTIN-3 FOR HEART FAILURE RISK STRATIFICATION IN PATIENTS AFTER ACUTE CORONARY SYNDROMES (ACS): INSIGHTS FROM THE SOLID-TIMI 52 TRIAL (2015) (2)
Effect of Darapladib onMajor Coronary Events After an Acute Coronary Syndrome The SOLID-TIMI 52 Randomized Clinical Trial (2014) (2)
Coronary Artery Patency and Survival in Clinical Trials (2004) (2)
Complimentary roles for N-terminal pro-B-type natriuretic peptide and spirometry to assess functional capacity in patients with complex mixed heart valve disease. (2010) (2)
Torrent of Troponin (2014) (2)
Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction. (2010) (2)
Cangrelor reduces the risk of ischemic complications in patients with single‐vessel and multi‐vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial (2017) (2)
The ATOLL trial of enoxaparin in primary percutaneous coronary intervention. (2010) (2)
Living alone and depressive symptoms are associated with major cardiovascular events in patients with chronic coronary heart disease (2015) (2)
THE ASSOCIATION BETWEEN CONCOMITANT PROTON-PUMP INHIBITOR USE AND CLINICAL OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED WITH PRASUGREL VERSUS CLOPIDOGREL AND MANAGED WITHOUT REVASCULARIZATION: INSIGHTS FROM THE TRILOGY ACS STUDY (2013) (2)
Left Ventricular Function as an Important Endpoint of Thrombolytic Trials (1992) (2)
Adding Insult to Injury: Are There Treatments for Myocardial Injury and Type 2 Myocardial Infarction? (2020) (2)
Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. (2005) (2)
Longitudinal study of a 9p21.3 SNP using a national electronic healthcare database. (2010) (2)
Angioplasty in acute myocardial infarction. (1987) (2)
Is thrombolytic therapy really better than conventional treatment in acute inferior myocardial infarction? (1995) (1)
In the transition from fibrinolysis to primary PCI, the HERO trials help refine STEMI ECG interpretation and Q wave analysis potentially alters future management (2018) (1)
SHORTER HOSPITAL STAYS AND OUTCOMES AFTER NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (2014) (1)
Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab. (2022) (1)
Impact of the ACUITY and TIMI major bleeding definitions on one-year mortality in patients with acute coronary syndromes (2007) (1)
Abstract 2812: Predictors of Reinfarction Following PCI or Medical Management in Patients With Persistent Total Occlusion After Myocardial Infarction: Results from the Occluded Artery Trial (OAT) (2007) (1)
Pharmacoeconomic Aspects of Treatment of Acute Myocardial Infarction with Thrombolytic Agents (1993) (1)
Blinded adjudication of non fatal reinfarction in patients following fibrinolytic therapy — results from the HERO-2 trial (2003) (1)
TCT-472 Prognosis of Patients Presenting with Non ST-Segment Elevation Myocardial Infarction and Non-obstructive Coronary Artery Disease: Propensity Score Matched Cohort from the ACUITY Trial (2012) (1)
Waiting room computer tablets to improve health literacy and cardiovascular outcomes (2021) (1)
Fibrinolysis for Acute Myocardial Infarction (2009) (1)
Comparison of High Sensitivity and 4th Generation Troponin Assays in an Inpatient Clinical Cohort (2010) (1)
Efficacy and Safety of Vorapaxar in Elderly Patients With Non-ST-Segment Elevation Acute Coronary Syndrome : Insights From the TRACER Trial (2013) (1)
Clinical Cardiology: New Frontiers Thrombolysis for Acute Myocardial Infarction (2007) (1)
Use of Secondary Prevention Medication Before and After an Acute Coronary Syndrome: Potential Long-Term Community Improvements, But Is This as ‘Good as it Gets’ After Hospital Discharge? (2009) (1)
Relationship between late infarct artery patency and outcome in the reperfusion era: is there a role for percutaneous revascularisation? (1999) (1)
Outcomes after ST-elevation myocardial infarction presentation to hospitals with or without a routine primary percutaneous coronary intervention service (ANZACS-QI 46). (2020) (1)
Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment: Analysis From the CHAMPION PHOENIX Trial (2019) (1)
Functional Status Following Stroke After Thrombolytic Therapy - Results From the GUSTO Trial (1994) (1)
Should bivalirudin be the anticoagulant of choice for percutaneous coronary intervention? (2005) (1)
Beyond pharmacology in heart attacks : coronary stents and stem cells (2007) (1)
Fatal atheromatous embolization during coronary angiography (2007) (1)
Chapter 39 The universal definition of myocardial infarction (2010) (1)
C-reactive protein is increased in aortic stenosis but not aortic regurgitation (2003) (1)
Comparison of EuroSCORE I, EuroSCORE II and AusSCORE for Detecting Outcomes After Isolated Coronary Artery Bypass Grafting (2013) (1)
Activated Partial Thromboplastin Time and Clinical Outcome Among Patients with Unstable Angina or Non-Q-Wave MI Treated with Intravenous Heparin (1995) (1)
REDUCTION OF TYPE 1 AND TYPE 2 MYOCARDIAL INFARCTIONS IN PATIENTS TREATED WITH ALIROCUMAB: INSIGHTS FROM THE ODYSSEY TRIAL (2019) (1)
predominant left ventricular failure: a report from the SHOCK Trial Registry The clinical profile of patients with suspected cardiogenic shock due to (2011) (1)
Reply to letter by Kirat and Kӧse: Maximizing information from a 12-lead electrocardiogram. (2015) (1)
IMPACT OF PRIOR CHRONIC ANTIPLATELET THERAPY ON SHORT- AND LONG-TERM ADVERSE EVENTS IN PATIENTS PRESENTING WITH AN ACUTE CORONARY SYNDROME: INSIGHTS FROM THE ACUITY TRIAL (2010) (1)
Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective (2021) (1)
Preventive angioplasty in myocardial infarction. (2014) (1)
Enoxaparin: a perspective on its use for coronary artery disease (2008) (1)
treatment after acute myocardial infarction . Safety and efficacy of repeat thrombolytic (1)
Heart, lung and circulation: flagship or millstone? (2004) (1)
Maori Have Worse Outcomes After Coronary Artery Bypass Grafting Than Europeans: Another Example of Ethnic Disparity in Cardiovascular Disease (2013) (1)
Management of non ST-elevation acute coronary syndrome (NSTEACS) patients in New Zealand (NZ): A longitudinal analysis. Results from the NZACS national audits of 2002, 2007 and 2012 (2014) (1)
A Simulation of Warfarin Maintenance Dose Requirement Using a Pharmacogenomic Algorithm in an Ethnically Diverse Cohort (2009) (1)
Clinical characteristics associated with major bleeding in NSTE ACS and the relationship between bleeding risk, ischemic events, and the vorapaxar effect : analysis from the TRACER trial (2012) (1)
Outcomes for Ximelagatran Compared with Warfarin According to INR Control: Results from SPORTIF III and V Atrial Fibrillation Trials. (2005) (1)
Ethnic Disparities in Coronary Artery Bypass Surgery: Comparing Maori and Europeans in New Zealand (2013) (1)
REDUCED DEATH, MYOCARDIAL INFARCTION, AND EARLY STENT THROMBOSIS WITH CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF BIVALIRUDIN: INSIGHTS FROM CHAMPION PHOENIX (2014) (1)
Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy). (2010) (1)
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX (2021) (1)
TCT-75 Cangrelor Improves Ischemic Outcomes In Patients With Multivessel Disease And Single Vessel Disease Undergoing PCI: Insights From The CHAMPION PHOENIX Trial (2015) (1)
Generalization of trial and registry cohort results to individual patients with cardiogenic shock (1999) (1)
Abstract 18682: Inflammatory Biomarkers for Prognostication of Outcomes in Stable Coronary Artery Disease - Experiences From the STABILITY Trial (2014) (1)
Abstract 12776: Non-ST-segment Elevation Acute Coronary Syndromes Patients without Angiographically Detected Obstructive Coronary Artery Disease are Low-risk but Not No-risk: A Meta-analysis of 8 Trials of 37,101 Patients (2010) (1)
Reduction in recurrent ischemic events with vorapaxar: results from TRACER (2013) (1)
ONE-YEAR MORTALITY INCREASED IN PATIENTS WITH PERI-PROCEDURAL MYOCARDIAL INFARCTION: INSIGHTS FROM THE CHAMPION TRIALS (2017) (1)
Patterns and outcomes of revascularization in patients with heart failure and/or left ventricular systolic dysfunction following acute myocardial infarction: observations from the VALIANT registry (2004) (1)
Thrombolytic eligibility. (1998) (1)
Collaboration With the Society of Geriatric Cardiology In the American Heart Association Council on Clinical Cardiology: Coronary Syndromes: A Scientific Statement for Healthcare Professionals From Acute Coronary Care in the Elderly, Part I: Non-ST-Segment-Elevation Acute (2007) (1)
PATIENTS WITH ACUTE CORONARY SYNDROME, ELEVATED ATHEROGENIC LIPOPROTEINS, AND PRIOR CORONARY ARTERY BYPASS GRAFTING DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIAL (2019) (1)
DIFFERENT ANALYSERS AND VARIABLE THRESHOLDS WITH TROPONIN TESTING IN NEW ZEALAND 2002–2007: IS IT TIME FOR SOME NATIONAL STANDARDISATION? (2008) (1)
Medical Treatment for Cardiogenic Shock (2002) (1)
Is thrombolytic therapy really better than conventional treatment in acute inferior myocardial infarction? (1995) (1)
Modifiable Risk Factors for Stroke in High-Risk Patients following Acute Myocardial Infarction: Insights from the VALIANT Study (2004) (1)
Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events (2021) (1)
Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution (2019) (1)
GROWTH DIFFERENTIATION FACTOR-15 (GDF-15) FOR PROGNOSTICATION OF OUTCOMES IN STABLE CORONARY ARTERY DISEASE: EXPERIENCES FROM THE STABILITY TRIAL (2015) (1)
Risk factors for stroke and the effect of cholesterol-lowering therapy with pravastatin (2000) (1)
Strokes and net clinical benefit. (1993) (1)
Issues raised by GUSTO. (1993) (1)
TCT-482 Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX (2014) (1)
Health Status and Clinical Outcomes in Older Adults With Chronic Coronary Disease: The ISCHEMIA Trial. (2023) (1)
Lack of correlation between ACT levels and outcomes in patients undergoing elective percutaneous coronary intervention with unfractionated heparin: the STEEPLE trial (2006) (1)
903 The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) Trial (2012) (1)
Thrombolytic therapy can be given to half of hospitalized patients with acute myocardial infarction (1996) (1)
CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF UNFRACTIONATED HEPARIN – INSIGHTS FROM CHAMPION PHOENIX (2017) (1)
Diabetes Mellitus And Cardiovascular Risk In Patients With Chronic Coronary Heart Disease (2016) (1)
Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial (2023) (1)
Brain natriuretic peptide: a predictor of cardiovascular outcome in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study (2005) (1)
Tooth Loss Is Independently Associated With Adverse Outcome But Not Myocardial Infarction In Patients With Chronic Coronary Heart Disease (2015) (1)
B‐Type Natriuretic Peptide and Long‐Term Cardiovascular Mortality in Patients With Coronary Heart Disease (2022) (1)
Pravastatin reduces the high rate of atherothrombotic complications in coronary heart disease patients with intermittent claudication (2001) (1)
BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk (2022) (1)
Acute increase in exercise capacity with milrinone: lack of correlation with resting hemodynamic responses. (1990) (1)
HORIZONS trial: a step forward for primary percutaneous coronary intervention (2009) (1)
Acute myocardial infarction: a true medical emergency. (1989) (1)
Type 1, Type 2 myocardial infarction and non-ischemic myocardial injury-opinion from the front lines. (2022) (1)
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study (2022) (1)
Determinants of mortality when primary LV failure complicates acute myocardial infarction (2005) (1)
Abstract 9904: Trends in Enrollment, Patient Characteristics, Treatments and Outcomes of Older Adults With Non-ST-segment Elevation Acute Coronary Syndromes (ACS) in Clinical Trials (2013) (1)
Have international guidelines failed? International variation in the treatment of acute MI: results of the VALIANT trial (2004) (1)
DOES SEVERITY OF LEFT VENTRICULAR REMODELING INFLUENCE THE RELATION BETWEEN MYOCARDIAL VIABILITY AND SURVIVAL WITH MEDICAL OR SURGICAL THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE AND LEFT VENTRICULAR DYSFUNCTION (2014) (1)
Alirocumab and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: Prespecified Sub-analysis from ODYSSEY OUTCOMES. (2022) (1)
Management of suspected acute coronary syndrome patients admitted to cardiology or non-cardiology services at Auckland City Hospital: implications for future national data collection. (2018) (1)
Underuse of reperfusion therapy in female patients: Insights from the TETAMI study and registry (The safety and efficacy of subcutaneous Enoxaparin versus intravenous unfractionated heparin and of myocardial infarction) (2003) (1)
Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies? (2000) (1)
Antianginal efficacy of perhexiline maleate in patients unresponsive to β adrenoreceptor blockade (1982) (1)
International differences in patients, care and outcomes associated with acute myocardial infarction (AMI): the HERO-2 trial (2003) (1)
Research forum abstractPoster session I: Cardiology—Moderator: Gregory J. Fermann, MD95: Early, Upstream, and Consistent Antithrombotic Therapy in High Risk Non-ST-Elevation ACS: Should Bivalirudin Be Initiated in the ED Prior to Coronary Angiography? (2006) (1)
Prioritizing waiting lists. (2000) (1)
Abstract 15281: Triglyceride Levels and Cardiovascular Outcomes After Acute Coronary Syndrome: Insights From the Odyssey Outcomes Trial (2020) (1)
Biomarkers in acute coronary syndromes (2012) (1)
Myocardial Infarction and Evolocumab. (2021) (1)
Low molecular weight heparins in acute ischaemic syndromes. (1998) (1)
Effect of simvastatin on the inflammatory response to coronary angioplasty (2003) (0)
and left Ventkular Function -After Intravenouk Thrombolysis for Acute Myocardial Infarction (1994) (0)
Abstract 4588: Regional Safety and Efficacy of Prasugrel Compared to Clopidogrel: A TRITON - TIMI 38 Analysis (2008) (0)
Leftventricular end-systolic volumeasthemajor determinant ofsurvival after recoveryfrom myocardial infarction (2015) (0)
METABOLIC RISK FACTORS AND THE EFFECT OF ALIROCUMAB ON CARDIOVASCULAR EVENTS IN PATIENTS AFTER ACUTE CORONARY SYNDROME: AN ANALYSIS OF THE ODYSSEY OUTCOMES RANDOMIZED CONTROLLED TRIAL (2021) (0)
Major bleeding is associated with increased one-year mortality and ischemic events in patients with acute coronary syndromes undergoing percutaneous coronary intervention: The ACUITY trial (2007) (0)
Abstract 11173: Effect of Alirocumab on Peripheral Artery and Venous Thromboembolic Events, and Relation to Lipoprotein(a) Concentration (2019) (0)
O047 Comparing Contemporary Coronary Artery Bypass Grafting Across Six Main Ethnic Groups of New Zealand: Another Example of Inequalities In Cardiovascular Disease (2014) (0)
Abstract 4589: Anti-thrombotic Strategies in Patients with Elevated Biomarkers Undergoing PCI: Results from the ACUITY Trial (2008) (0)
REDUCED IMMEDIATE ISCHEMIC EVENTS WITH CANGRELOR IN PCI USING THE UNIVERSAL DEFINITION OF MI: POOLED ANALYSIS OF THE CANGRELOR VERSUS STANDARD THERAPY TO ACHIEVE OPTIMAL MANAGEMENT OF PLATELET INHIBITION TRIALS (2011) (0)
A comparison of the management and in-hospital outcomes of acute coronary syndrome (ACS) patients in Australia and New Zealand: Results from the binational SNAPSHOT ACS 2012 audit (2015) (0)
Frailty is associated with worse outcomes in acute coronary syndromes: outcomes in TRILOGY (2013) (0)
Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements (2020) (0)
Pre-surgical Cardiopulmonary Exercise (CPEX) Testing Predicts Outcomes in Complex Heart Valve Disease (2009) (0)
Chapter 18 – Acute Coronary Syndromes (2007) (0)
IMPACT OF PRIOR CLOPIDOGREL USE ON ISCHEMIC OUTCOMES AMONG MEDICALLY MANAGED PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROMES: RESULTS FROM THE TRILOGY ACS TRIAL (2014) (0)
Risk models for contemporary isolated coronary artery bypass grafting: comparison of EuroSCORE I, EuroSCORE II and AusSCORE (2013) (0)
Abstract 16422: Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes (2011) (0)
Abstract 16968: Troponin I Is an Independent Predictor of Long-Term Coronary Events Following Myocardial Infarction or Unstable Angina: Results from the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Trial (2011) (0)
When to Use Glycoprotein IIb/IIIa Inhibitors and Which One to Use: Abciximab, Tirofiban, or Eptifibatide? (2009) (0)
815-3 Long-term survivors of cardiogenic shock enjoy good functional capacity, and a strategy of early revascularization is protective against functional class deterioration and death (2004) (0)
CardioPulse The 2010 version of the ESC Guidelines for the management of grown-up adult congenital heart (2010) (0)
CLINICAL FEATURES AND OUTCOMES OF PATIENTS WITH TYPE 2 MYOCARDIAL INFARCTION: INSIGHTS FROM THE TRACER TRIAL (2016) (0)
Chronic kidney disease, ejection fraction and heart failure in patients with occluded infarct-related arteries post-myocardial infarction: Data from the occluded artery trial (2006) (0)
Body Mass Index and Outcomes After Coronary Artery Bypass Grafting: Is There an Association? (2013) (0)
Contents (2020) (0)
plerenone Reduces Mortality 0 Days After Randomization Following cute Myocardial Infarction in Patients With eft Ventricular Systolic Dysfunction and Heart Failure (2005) (0)
Is there an acceptable ceiling for bleeding for an antithrombotic drug dose to be tested in a phase 3 trial? (2009) (0)
Acute coronary syndromes: the clot is there. (1999) (0)
Impact of Bivalirudin Monotherapy on 30-day Outcomes in Patients with Acute Coronary Syndromes and Complex Coronary Stenoses Undergoing Percutaneous Coronary Intervention (2009) (0)
The prevalence of low HDL cholesierol in patients undergoing coronary arteriography for chest pain (1991) (0)
Influence of corrected TIMI frame counts on late survival of patients with acute coronary syndromes without ST-segment elevation (2000) (0)
Persistent psychological distress and mortality in patients with stable coronary artery disease in the LIPID trial (2015) (0)
Abstract 2267: Can Patients with Acute Anterior Myocardial Infarction and Right Bundle Branch Block Be Further Risk-Stratified within 60 Minutes of Fibrinolytic Therapy? (2006) (0)
REDUCTION OF MYOCARDIAL INFARCTION WITH VORAPAXAR: RESULTS FROM THE TRA·CER TRIAL (2012) (0)
New therapeutic approaches Beyond pharmacology in heart attacks : coronary stents and stem cells (2007) (0)
Predictors of incident heart failure in patients with stable coronary heart disease (2013) (0)
Comparison of fat intake in Australian and New Zealand CHD patients: The lipid (long-term intervention with pravastatin in ischaemic disease) study (2002) (0)
Suspected ACS Patients Admitted and Discharged to Cardiology or Non-Cardiology Care in Auckland City Hospital: Insight from SNAPSHOT 2012 and Implications for Future National Data Collection (2017) (0)
Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial (2014) (0)
Regional variations in treatments and outcomes of reinfarction in the HERO-2 trial (2003) (0)
Effects of four thrombolytic regimens in elderly patients (1998) (0)
Utility of high-sensitivity troponins after combined aortic valve replacement and coronary artery bypass grafting towards defining myocardial infarction (2015) (0)
POST-ACUTE CORONARY SYNDROME PATIENTS WITH POLYVASCULAR DISEASE DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: ODYSSEY OUTCOMES (2019) (0)
Lifti gt he Smoke-Screen: The Enigma of Outcome ,n Smokers After Myocardial Infarction (1995) (0)
Abstract 3073: Development and Validation of a Bleeding Risk Model for Major Bleeding in Patients Undergoing Elective Percutaneous Coronary Intervention: the STEEPLE Trial (2006) (0)
N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE IN AORTIC STENOSIS: RESULTS FROM THE NZ HEART VALVE STUDY (2008) (0)
Prognositc Utility of High-Sensitivity Troponin Level on Admission for Outcomes After ST-Elevation Myocardial Infarction (2013) (0)
The effect of age on early death and stroke rates in patients with heart failure after acute myocardial infarction (2003) (0)
Hirudin was superior to heparin in preventing CV death, MI and refractory angina, in patients with unstable angina or MI without ST elevation (1999) (0)
Effect of ivabradine on heart rate variability in patients with stable coronary artery disease (2015) (0)
PCV65 CHANGE IN HEALTH-RELATED QUALITY OF LIFE FOLLOWING NON-FATAL CARDIOVASCULAR EVENTS IN POST-MYOCARDIAL INFARCTION PATIENTS (2008) (0)
Bleeding and blood transfusion rates are higher among acute coronary syndrome patients in the United States than in other countries (2005) (0)
Abstract 13270: Relationship of Longitudinal Measurements of Biomarkers of Hemodynamic Stress, Systemic Inflammation, and Platelet Reactivity with Ischemic Outcomes in Non-ST-Elevation Acute Coronary Syndrome Patients Managed Without Revascularization (2014) (0)
Abstract 13208: Time-Dependent Interactions of Prasugrel vs Clopidogrel on the Long-Term Risks of Stroke after Acute Coronary Syndromes: Results from the TRILOGY ACS Trial (2014) (0)
Thrombolytic therapy. Introduction. (1991) (0)
Utility of high-sensitivity troponins after combined coronary artery bypass grafting towards and aortic valve replacement for diagnosing myocardial infarction (2015) (0)
INCIDENCE AND IMPACT OF STENT THROMBOSIS DURING PERCUTANEOUS CORONARY INTERVENTION: COMPARISON OF CANGRELOR AND CLOPIDOGREL FROM THE CHAMPION PHOENIX TRIAL (2014) (0)
Comparison of outcomes in patients randomized to warfairn according to anticoagulant control: results from Sportif III (2007) (0)
Females are Associated with Higher Mortality After Coronary Artery Bypass Grafting (2013) (0)
IMPACT OF PRIOR CEREBROVASCULAR EVENTS ON ISCHEMIC AND BLEEDING OUTCOMES WITH CANGRELOR IN PERCUTANEOUS CORONARY INTERVENTION (2016) (0)
TCT-724 Impact of Coronary Calcification Severity on Clinical Outcomes After Contemporary PCI – Insights From the CHAMPION PHOENIX Trial (2017) (0)
Management of patients with non-ST-elevation acute coronary syndromes (2001) (0)
The Role of Ultra-fast Computed Tomography in the Assessment of Suspected or Known Coronary Artery Disease (2003) (0)
Reply to: Role of aldosterone receptor antagonist eplerenone in aortic steroids (2009) (0)
The effect of tirofiban vs heparin in patients presenting with non-Q-wave myocardial infarction (1997) (0)
Multiple Troponin Testing For Acute Coronary Syndrome Patients: Potential For Significant Cost Savings (2009) (0)
A symposium : anticoagulant therapy : new promises and challenges (1998) (0)
Clinical and Angiographic Predictors of Death or Myocardial Infarction in Diabetics with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An ACUITY Subanalysis (2009) (0)
THE RELATIONSHIP BETWEEN TOOTH LOSS, CARDIOVASCULAR BIOMARKERS AND OUTCOMES IN PATIENTS WITH STABLE CORONARY HEART DISEASE (2016) (0)
O220 Performance Of Euroscore I, Euroscore Ii And Society Of Thoracic Surgeon’S Risk Models To Predict Adverse Outcomes After Isolated Coronary Artery Bypass Grafting (2014) (0)
The roles for coronary surgery and angioplasty in the management of patients with stable angina: evidence and decision making. (1998) (0)
High Mortality and Morbidity in Acute Coronary Syndrome Patients who Received Medical (Non-revascularisation) Management (2010) (0)
1042-82 White blood cell count predicts higher risk of intermediate-term outcomes in patients stabilized after acute coronary syndromes: Observations from the SYMPHONY and 2ndSYMPHONY trials (2004) (0)
Evolution of the Coronary Microcirculation After Restoration of Epicardial Blood Flow in STEMI. (2022) (0)
PATENCY OF INFARCT-RELATED CORONARY ARTERY. AUTHOR'S REPLY (1994) (0)
Risk Models Performance in Predicting Dialysis for Acute Kidney Injury After Coronary Artery Bypass Grafting (2016) (0)
Relationship Between Body Mass Index and Outcomes After Coronary Artery Bypass Grafting (2013) (0)
Abstract 2564: Predictors of Early Stent Thrombosis in Patients with Acute Coronary Syndromes in the Drug-Eluting Stent Era: Analysis from the ACUITY trial (2007) (0)
1. Risk Assessment in Acute Cornory Syndromes (2005) (0)
Abstract 16912: Visit-to-visit Variability of Blood Pressure Predicts Cardiovascular Outcome in Patients With Coronary Artery Disease From the Stability Trial (2016) (0)
eperfusion Strategies for Acute yocardial Infarction in the Elderly enefits and Risks (2016) (0)
Re: Letter responding to “Dabigatran for patients with a mechanical valve – by F. Van de Werf and J. Eikelboom” (2012) (0)
Terminology of acute coronary syndromes and definition of myocardial infarction (2011) (0)
Ventricular Arrhythmias in€Patients With a Continuous-Flow Left Ventricular Assist Device (0)
Abstract 550: Prognostic Significance of Evolving ST-Segment Depression on Admission and Early Repeat Electrocardiograms in Non-ST Elevation Acute Coronary Syndromes - Insights from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitor (SYNERGY) (2008) (0)
SHORT-DURATION, VERY HIGH-INTENSITY LIPID-LOWERING THERAPY RESULTS IN PROLONGED REDUCTION OF CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROME (2023) (0)
All Cause Mortality Following an Acute Coronary Syndrome (ACS) Admission: Six Year Follow-up of the 2002 New Zealand (NZ) Acute Coronary Syndromes Audit (2012) (0)
Cangrelor in Older Patients Results Association Between Age and Cardiovascular Events in CHAMPION PHOENIX (2017) (0)
Comparison of society of thoracic surgeon's risk models with EuroSCORE and EuroSCORE II at adverse outcome prediction after coronary artery bypass grafting (2014) (0)
Recurrent Ischaemic Heart Disease Hospitalisations in New Zealand are Declining More Rapidly than First Hospitalisations: An ANZACS-QI National Data-Linkage Study (2016) (0)
Systems of Care (2008) (0)
Meta-Analysis of Risk Scores to Predict Bleeding in Acute Coronary Syndrome (2017) (0)
LIPOPROTEIN(A) AND CARDIOVASCULAR OUTCOMES IN WOMEN AND MEN AFTER AN ACUTE CORONARY SYNDROME: A POST HOC ODYSSEY OUTCOMES TRIAL ANALYSIS (2023) (0)
Abstract 13144: MicroRNA Sequencing Highlights Regulatory Networks Upstream of Osteopontin and B-type Natriuretic Peptide in Acute Coronary Sydrome (2016) (0)
Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels? Clinical Investigation and Reports (2002) (0)
Depressive symptoms, health status and mortality in the lipid study (2003) (0)
Abstract 15520: Incorporating Novel Biomarkers Significantly Improves Risk Stratification for Coronary Heart Disease Patients: the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Trial (2011) (0)
PM461 Higher Pre-Catheterisation High-Sensitivity Troponin Levels In Maori And Pacific Patients With St-Elevation Myocardial Infarction In New Zealand: Implications For Reducing Ethnic Disparities In Cardiovascular Outcomes (2014) (0)
New Antiplatelet Strategies in the Adjunctive Treatment of Acute Myocardial Infarction (1997) (0)
Hirudin is modestly more effective than heparin in the treatment of acute coronary syndromes. (1997) (0)
755-6 Neurosurgical Evacuation for Intracranial Hemorrhage Associated with Improved Outcome in GUSTO (1995) (0)
EFFECTS OF ALIROCUMAB ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH PREVIOUS MYOCARDIAL INFARCTION: SUBANALYSIS FROM THE ODYSSEY OUTCOMES TRIAL (2021) (0)
Abstract 12777: More Bleeding but No Additional Efficacy with Increasing Age in High-risk ACS Patients Treated with Early vs. Delayed, Provisional Eptifibatide (2010) (0)
Comparison of catheterization lab initiated abciximab and double-bolus eptifibatide during percutaneous coronary intervention in acute coronary syndromes: an ACUITY substudy (2007) (0)
Coronary heart disease The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction (2007) (0)
DAYS ALIVE OUT OF HOSPITAL WITH INITIAL INVASIVE VS CONSERVATIVE MANAGEMENT IN THE ISCHEMIA TRIAL (2021) (0)
Clinical validation of BARC definitions of bleeding after an ACS in the TRACER trial (2013) (0)
WHAT THRESHOLD SHOULD BE USED TO DEFINE PERCUTANEOUS CORONARY INTERVENTION-RELATED MYOCARDIAL INFARCTION? AN APPROACH BASED ON CLINICAL RELEVANCE FROM EARLY ACS AND SYNERGY (2011) (0)
Abstract 10288: Revealing the Full Meaning of Lead aVR ST Changes in ST Elevation Myocardial Infarction (2010) (0)
Data on eligibility for thrombolytic treatment can indeed be generalised (1997) (0)
Acute Coronary Syndrome Patients Treated with CABG Surgery: Suboptimal Use of Secondary Prevention Medications at Review 3 Years Later (2010) (0)
Natriuretic peptide plasma levels remain elevated six months after aortic valve replacement for severe aortic stenosis (2003) (0)
ACHIEVEMENT OF NEW EUROPEAN DYSLIPIDEMIA-GUIDELINE LOW-DENSITY LIPOPROTEIN CHOLESTEROL TREATMENT GOALS AFTER ACUTE CORONARY SYNDROME: INSIGHTS FROM ODYSSEY OUTCOMES (2020) (0)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (0)
Abstract 2463: The Relationship Between Obesity, Diabetes and Outcomes in Elective Percutaneous Coronary Intervention: Results from the STEEPLE Trial (2006) (0)
Influence of cardioplegia techniques on outcomes after aortic valve replacement (2014) (0)
Clinical Features and Outcomes of Patients with Type 2 Myocardial Infarction : Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome ( TRACER ) (2017) (0)
EFFECT OF ALIROCUMAB ON FIRST AND TOTAL REVASCULARIZATIONS IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME IN THE ODYSSEY OUTCOMES TRIAL (2020) (0)
PW291 Influence Of Cardioplegia Techniques On High-Sensitivity Troponin Release And Adverse Outcomes After Aortic Valve Replacement (2014) (0)
IMPACT OF PERIPROCEDURAL MYOCARDIAL INFARCTION IN CONTEMPORARY PCI: POOLED PATIENT-LEVEL DATA FROM THE CHAMPION TRIALS (2017) (0)
Abstract 1803: Catheterization without In-hospital Revascularization is Associated with Increased Long-term Mortality in Patients with Non-ST Elevation Myocardial Infarction and Significant Coronary Artery Disease (2007) (0)
Abstract 16787: Use of Thienopyridine Prior to Presentation for Acute Coronary Syndromes and Association With Safety and Efficacy of Vorapaxar: Insights From the TRACER Study (2014) (0)
Neither periprocedural pregnancy-associated plasma protein A nor C-reactive protein levels predict restenosis (2003) (0)
Abstract 16755: Association Between Achievement of Risk Factor Standard of Care Goals and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease in the STABILITY Trial (2015) (0)
Elevation Myocardial Infarction Treated With Fibrinolysis Association of Mortality With Years of Education in Patients With ST-Segment (2012) (0)
Is the Mortality Risk Following an Acute Coronary Syndrome (ACS) Admission to a Non-intervention Centre Related to Access to Cardiac Angiography? Eighteen Month Follow-up of the 2002/2007 New Zealand (NZ) ACS Audits (2012) (0)
Prediction of frame counts 90 minutes after thrombolysis by myocardial protein levels at presentation (2000) (0)
Diagnosis of myocardial infarction after aortic valve replacement with high-sensitivity troponins (2014) (0)
The management of myocardial infarction: an update. (1990) (0)
Direct thrombin inhibition in percutaneous coronary intervention (2007) (0)
Bias in the evaluation of evidence linking depression to cardiovascular mortality: reply (2004) (0)
1117-87 Does the presence of Q waves in the infarct-leads at the presentation of an ST elevation myocardial infarction predict 30-day outcome after fibrinolytic therapy? Results from the HERO-2 trial (2004) (0)
Comparison of Octogenarians and Septuagenarians Undergoing Coronary Artery Bypass Surgery (2018) (0)
Abstract 16894: The Effect of Cangrelor on Cardiovascular and Bleeding Events in Patients With Peripheral Artery Disease - Insights From CHAMPION PHOENIX (2015) (0)
Suspected ACS Patients Admitted and Discharged from Cardiology or Non-Cardiology Management at Auckland City Hospital: Insights from the Comprehensive SNAPSHOT 2012 Audit and Implications for Future National Data Collection (2017) (0)
2212Body mass index and its association to cardiovascular outcomes in patients with stable coronary heart disease - experiences from the STABILITY study (2019) (0)
Prolonged and sustained reduction in total and coronary mortality in patients assigned pravastatin in the LIPID trial during two further years of follow-up (2000) (0)
TCT-2 Incidence and Impact of Totally Occluded Culprit Arteries in Patients with Non-ST-segment Elevation (2014) (0)
More aggressive thrombolytic treatment increases stroke risk Results from the GUSTO Trial (1994) (0)
AN EARLY INVASIVE STRATEGY IN ELDERLY PATIENTS WITH ACUTE CORONARY SYNDROMES (ACS)—ARE WE MAKING A DIFFERENCE?: AN AUDIT OF CCU ADMISSIONS 2001 AND 2006 AT AUCKLAND AND GREEN LANE HOSPITAL (2008) (0)
Is thrombin a pharmacological target during reperfusion? (1999) (0)
Low-density lipoprotein cholesterol <50 mg/dL is an appropriate target after acute coronary syndrome: propensity score-matched analysis of the ODYSSEY OUTCOMES trial (2020) (0)
Abstract 15659: Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Non-ST-Segment Elevation Acute Coronary Syndrome Patients in TRACER (2012) (0)
Increased risk of ICH with standard contraindications to fibrinolytic therapy Results from ASSENT-2 (2001) (0)
Reduces Mortality 0 Days After Randomization Following cute Myocardial Infarction in Patients With eft Ventricular Systolic Dysfunction and Heart Failure (2016) (0)
Early ST recovery, infarct artery flow and long-term outcome after acute myocardial infarction (2000) (0)
Comparative mortality analysis of the International TPA/SK trial. An unexplained variance (1992) (0)
Abstract 11149: Effect of Low-density Lipoprotein Cholesterol Lowering With Alirocumab on Stroke in ODYSSEY OUTCOMES (2019) (0)
Zooming in on the Enigmas of Type 2 Myocardial Infarction. (2022) (0)
Differences in the profile and risk of acute coronary syndrome patients stratified by country-level human development index: results from the global TRILOGY ACS trial (2013) (0)
BLEEDING RISK MODELS IN ACUTE CORONARY SYNDROME: META-ANALYSIS OF PERFORMANCE (2017) (0)
Abstract 15834: Evolution of Differences in Women and Men With Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From Clinical Trials Over 15 Years (2013) (0)
PM150 Pre-Catheterisation High-Sensitivity Troponin T Level Predicts Major Adverse Cardiovascular Events After St-Elevation Myocardial Infarction (2014) (0)
Comparison of heparin plus IIb/IIIa inhibition versus bivalirudin with or without IIb/IIIa inhibition in patients with acute coronary syndromes undergoing percutaneous coronary intervention: The ACUITY trial (2006) (0)
Post-hoc analyses of darapladib, an oral Lp-PLA(2) inhibitor, in phase III cardiovascular outcomes trials may inform investigation in diabetic macular edema (2015) (0)
Increasing left ventricular sphericity is associated with decreased survival even in patients with TIMI-3 flow or inferior infarction (2002) (0)
Primary Percutaneous Coronary Intervention for all Patients with ST Elevation Myocardial Infarction—The Initial Experience at Auckland City Hospital 2006/2007 (2011) (0)
EFFECTS OF ALIROCUMAB IN PATIENTS WITH RECENT ACS AND A HISTORY OF HEART FAILURE: AN ANALYSIS OF THE ODYSSEY OUTCOMES TRIAL (2021) (0)
Eligibility Criteria for Thrombolytic Therapy in Clinical Trials (2007) (0)
Sheath management in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial (2006) (0)
THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL (2018) (0)
Cardiac Tamponade in the Fibrinolytic Area: Analysis of over 100.000 ST-Segment Myocardial Infraction Patients (2004) (0)
TEMPORAL TRENDS OVER 15 YEARS IN CLINICAL TRIALS OF NON-ST ELEVATION ACUTE CORONARY SYNDROMES: MORE AGGRESSIVE TREATMENT YIELDS SIMILAR MORTALITY DESPITE HIGHER-RISK PROFILES (2010) (0)
ASSOCIATION BETWEEN VERY LOW LEVELS OF BASELINE HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND INCREASED LONG-TERM MORTALITY IN MEDICALLY MANAGED ACUTE CORONARY SYNDROME PATIENTS (2014) (0)
Glycoprotein IIb/IIIa inhibitors (2008) (0)
EFFICACY OF CANGRELOR IN CONGESTIVE HEART FAILURE PATIENTS UNDERGOING PCI: A SUBGROUP ANALYSIS FROM THE CHAMPION POOLED DATABASE (2016) (0)
PROGNOSTIC VALUE OF BASELINE CARDIOVASCULAR MAGNETIC RESONANCE IMAGING MEASURES OF LEFT VENTRICULAR GEOMETRY AND FUNCTION IN 366 PATIENTS UNDERGOING SURGERY FOR ISCHEMIC CARDIOMYOPATHY: RESULTS FROM NIH SPONSORED STICH TRIAL (2014) (0)
Coronary Artery Bypass Grafting (2009) (0)
P-450: Prognostic information derived from blood pressure indices in patients with left ventricular systolic dysfunction early post-myocardial infarction (2003) (0)
P625Screening multiple biomarkers for associations with major coronary events (2018) (0)
acute myocardial infarction . patency after streptokinase treatment for Aspirin does not improve early arterial (0)
Improved rates of secondary prevention medication following hospitalisation for an acute coronary syndrome (ACS) in New Zealand (NZ): Results from the NZ ACS national audits of 2002, 2007 and 2012 (2014) (0)
Cardioplegia in contemporary coronary artery bypass grafting: Effects on high-sensitivity troponins and outcomes (2014) (0)
Il-ADRENERGIC BLOCKADE Efficacy and safety of timolol for prevention of supraventricular tachyarrhythmias after coronary artery bypass surgery (2005) (0)
Effect of alirocumab on incidence of atrial fibrillation after acute coronary syndromes: insights from ODYSSEY OUTCOMES (2020) (0)
New onset atrial fibrillation following myocardial infarction is a strong independent predictor of mortality in patients treated with primary percutaneous coronary intervention (2008) (0)
CAN A SIMPLE ADJUSTMENT FOR FAMILY HISTORY OF PREMATURE CARDIOVASCULAR DISEASE IMPROVE THE FRAMINGHAM-BASED RISK SCORE FOR YOUNG PEOPLE PRESENTING WITH AN ACUTE CORONARY SYNDROME? (2008) (0)
Drug eluting stents in patients with acute coronary syndromes undergoing percutaneous coronary intervention: The ACUITY trial (2006) (0)
In acute coronary syndromes patients with ST segment depression have improved late survival following early revascularisation (2000) (0)
Impact of guideline-recommended versus non-guideline-recommended β-blocker and Doppler echocardiographic parameters on 1-year mortality in Thai ischemic cardiomyopathy patients: A prospective multicenter registry (2020) (0)
APOLIPOPROTEIN B, PCSK9 INHIBITION WITH ALIROCUMAB, AND ISCHEMIC CARDIOVASCULAR EVENTS AFTER ACUTE CORONARY SYNDROME: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIAL (2020) (0)
Risk factors for 10-year coronary heart disease mortality in patients with prior acute coronary syndromes: The LIPID cohort (2005) (0)
DUAL ANTIPLATELET THERAPY AND OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION AND ACUTE CORONARY SYNDROMES (2014) (0)
Abstract 6180: Resolution of ST-Segment Depression: A New Prognostic Marker of Clinical Outcome in ST-Segment Elevation Myocardial Infarction (2008) (0)
THE EFFECT OF PLATELET INHIBITON BY CANGRELOR AMONG OBESE PATIENTS UNDERGOING CORONARY STENTING: INSIGHTS FROM THE CHAMPION TRIALS (2019) (0)
Tirofiban: A Paradigm for ‘‘Small-Molecule’’ Glycoprotein IIb/IIIa Receptor Antagonists? (2002) (0)
Adjunctive Antithrombotic Therapy for St‐Elevation Acute Myocardial Infarction (2007) (0)
Abstract 18938: Prognostically Important Myocardial Infarctions are Markedly Underreported in Patients Undergoing Percutaneous Coronary Intervention: Insights from CHAMPION PHOENIX (2014) (0)
Dialysis-requiring Acute Kidney Injury after Coronary Artery Bypass Grafting: Performance of Six Risk Models (2016) (0)
Abstract 17504: Time-dependent Association of Circulating microRNAs With Death and Myocardial Infarction After Non-ST Elevation Acute Coronary Syndrome (2016) (0)
Abstract 14813: Pre-Treatment With Thienopyridines Reduces The Amount of Myonecrosis in Acute Coronary Syndrome Patients Invasively Managed: Insights from the CHAMPION trials (2010) (0)
Research in the Antipodes at Green Lane. (2020) (0)
COMPARISON OF BLEEDING RISK PREDICTION MODELS WITH DUAL ANTI-PLATELET THERAPY TREATMENT AMONG PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED MEDICALLY WITHOUT REVASCULARIZATION (2019) (0)
Lipid modifying therapy for long-term survivors of myocardial infarction (1998) (0)
Abstract 15711: Sleep Quality and Major Cardiovascular Events in Patients With Stable Coronary Heart Disease (2017) (0)
Abstract P195: Long-Term Outcomes Associated with Hospital-Acquired Thrombocytopenia Among Patients with Acute Coronary Syndrome (2011) (0)
Bivalirudin Not Superior to Unfractionated Heparin in Patients Receiving 600 mg Clopidogrel Prior to PCI (2008) (0)
Is the combination of valsartan and captopril better than captopril alone in patients with heart failure and left ventricular systolic dysfunction after myocardial infarction? results of VALIANT (2004) (0)
, established coronary heart disease : baseline results from the STABILITY study Secondary prevention and risk factor target achievement in a global , high-risk population with (2013) (0)
PW127 Prognostic Utility Of High-Sensitivity Troponin T Pre-Catheterisation In Patients Without Significant Coronary Artery Disease (2014) (0)
Correction (1960) (0)
Single bolus tenecteplase was equivalent to front-loaded alteplase for 30-day mortality after acute MI (2000) (0)
Resolution of ST-Segment Depression: A New Prognostic Marker of Clinical Outcome in ST-Segment Elevation Myocardial Infarction (2008) (0)
P3640Association of ceramide and phospholipid levels and cardiovascular events in stable coronary heart disease: findings from the STABILITY Biomarkers substudy (2019) (0)
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION (2022) (0)
Influence of body mass index on mortality following high-risk myocardial infarction: the VALIANT experience (2004) (0)
Abstract 12243: Associations Between Physical Activity and Prognostic Biomarkers in Patients With Stable Coronary Heart Disease in the STABILITY Trial (2015) (0)
A decade of improvement in investigations received and treatments delivered to New Zealand (NZ) ST-elevation myocardial infarction (STEMI) patients: Results from the NZACS national audits of 2002, 2007 and 2012 (2014) (0)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (0)
Socioeconomic status and outcome among Australians in the LIPID study (2001) (0)
Chapter 8 – Direct Thrombin Inhibitors (2004) (0)
Anti-xa activity and outcomes in patients undergoing elective percutaneous coronary intervention with intravenous enoxaparin: The STEEPLE trial (2006) (0)
Acute Coronary Syndrome Patients Treated with Percutaneous Coronary Intervention: Potential for Significant Socio-Economic Burden from Adverse Events Due to Poor Cholesterol Control at Review 3 Years Later (2010) (0)
Abstract 13846: The Relationship of Platelet Function Measurements with Bleeding Outcomes During Long-term Treatment with Dual Antiplatelet Therapy in Medically Managed NSTE-ACS Patients (2014) (0)
Bivalirudin reduces ischemic and hemorrhagic complications of percutaneous coronary intervention: Pooled data from 10 prospective studies in 6,134 patients (2003) (0)
Abstract 12951: Predictors of Incident Heart Failure in Patients with Stable Coronary Heart Disease (2013) (0)
SELF-REPORTED GENERAL HEALTH AND OUTCOMES IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: EXPERIENCES FROM THE GLOBAL STABILITY TRIAL (2016) (0)
ST Elevation Myocardial Infarction: Suboptimal Use of Secondary Prevention Medications at Review Five Years Later (2011) (0)
Abstract 3289: Novel Biomarkers Add Prognostic Value over Traditional Risk Factors for Nonhemorrhagic Stroke in Patients with Known Coronary Heart Disease: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Trial (2012) (0)
Primary Percutaneous Coronary Intervention for Patients with St Elevation Myocardial Infarction—Past and Present at Auckland City Hospital (2012) (0)
Abstracts of the XV Swedish Cardiovascular Spring Meeting. Göteborg, Sweden. April 17–19, 2013. (2013) (0)
INTERNATIONAL COMPARISONS OF HEALTH STATUS OUTCOMES IN PATIENTS UNDERGOING INITIAL INVASIVE VERSUS CONSERVATIVE MANAGEMENT FOR CHRONIC CORONARY DISEASE: INSIGHTS FROM THE ISCHEMIA TRIAL (2023) (0)
Abstract 16738: International Variation in Management and Clinical Outcome of Patients With Type 2 Diabetes and Heart Failure: Insights From TECOS (2017) (0)
coronary syndromes: results from the ACUITY trial The impact of the coronary collateral circulation on outcomes in patients with acute (2015) (0)
Long-term safety and effectiveness of cholesterol lowering with pravastatin treatment over 11 years: The LIPID trial extension (2005) (0)
Risk factors for ischemic stroke in patients with acute myocardial infarction treated with thrombolytic therapy (1996) (0)
Myocardial Infarction After Coronary Artery Bypass Grafting Diagnosed with High-Sensitivity Troponin T and Associations with Mortality (2013) (0)
Elderly patients should not be denied fibrinolytic therapy (2007) (0)
Reply: the latest generation of troponin immunoassays: the "cholesterol" of the third millennium? (2014) (0)
Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations. (2023) (0)
Abstract 2363: Antiarrhythmic Drug Therapy for Sustained Ventricular Arrhythmias Complicating Acute Myocardial Infarction (2009) (0)
Safety andefficacy ofrepeatthrombolytic treatmentafter acutemyocardial infarction (1990) (0)
Abstract 14328: Relation of Lipoprotein(a) Levels to Incident Diabetes and Modification by Alirocumab Treatment: An Analysis of the Odyssey Outcomes Trial (2020) (0)
Screening for cardiovascular disease : reply (2004) (0)
Edinburgh Explorer Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (2018) (0)
Effects of pravastatin on cardiovascular endpoints in patients with previous unstable angina (2000) (0)
Predictors of low physical activity in patients with stable coronary heart disease in the global STABILITY study (2012) (0)
Abstract 19024: Regulation of Platelet Reactivity Identified Through MicroRNA Profiling in Acute Coronary Syndrome (2016) (0)
Major Delays Experienced by Patients Waiting for In-Hospital Cardiac Angiography and Coronary Artery Bypass Graft Surgery Result in Significant Extra Health Care Costs (2009) (0)
Usefulness of concordant ST elevation and V1-3 st depression in risk stratifying patients with presumed acute myocardial infarction and left bundle branch block (2003) (0)
Klaidman S. Saving the Heart: The Battle to Conquer Coronary Disease. New York: Oxford University Press, 2000. ISBN 0-19-511279-2, 288 pages, illustrated, hardback. £22. (2005) (0)
Iconographies supplémentaires de l'article : Comparison of Four Risk Scores for Contemporary Isolated Coronary Artery Bypass Grafting (2014) (0)
Risk Assessment in Patients with Non-ST Elevation Acute Coronary Syndromes (2003) (0)
Validation of the universal definition for type 5 myocardial infarction using high-sensitivity troponin T and dual ECG and echocardiographic criteria (2013) (0)
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet (2012) (0)
Abstract 10795: Alirocumab and Cardiovascular Outcomes in Older Patients After an Acute Coronary Syndrome: An ODYSSEY OUTCOMES Trial Analysis (2019) (0)
INCIDENCE AND PREDICTORS OF SUDDEN CARDIAC DEATH AFTER HOSPITALIZATION FOR NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: AN ANALYSIS FROM THE TRACER TRIAL (2013) (0)
Differential Prognostic Implications of Peak Troponin Level in Acute Coronary Syndrome Treated With and Without Revascularization (2013) (0)
Is thrombolytic therapy really better than conventional treatment in acute inferior myocardial infarct. (1996) (0)
Prospective evaluation of a chest pain pathway in the coronary care unit at green lane hospital; One year follow up study (2003) (0)
Associations between psychosocial burden and prognostic biomarkers in patients with stable coronary heart disease – a STABILITY substudy (2020) (0)
Paradoxical use of angiography with advancing age: insights from an international trial population (2002) (0)
Increased left ventricular sphericity at 3 weeks is associated with decreased survival even in patients with inferior myocardial infarction or TIMI-3 flow (2003) (0)
Long-term outcomes for women vs. men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the TRILOGY ACS trial (2015) (0)
Preventive cardiologyAbstractWhite Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin (2005) (0)
Abstract 3804: Safety and Effectiveness of Bivalirudin in Non ST-Segment Elevation Acute Coronary Syndromes by Duration of Upstream Infusion in the ACUITY Trial: Implications for Emergency Department and Upstream Management (2006) (0)
VEGF-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease. (2023) (0)
Abstract 4509: Individual Patient Risks of Major Bleeding and Myocardial Infarction and Their Implications for Mortality and for Treatment Choice in Acute Coronary Syndromes: Findings From the ACUITY Trial (2009) (0)
Sex Differences in 1-Year Mortality Following Acute Coronary Syndromes (2008) (0)
Relationship Between Admission High-Sensitivity Troponin Levels and Outcomes After ST-elevation Myocardial Infarction (2013) (0)
Abstract 16290: Long-Term Safety and Effectiveness of Cholesterol Lowering with Pravastatin Treatment Over 11 Years: The Lipid Study Extension (2012) (0)
Abstract 2217: Impact of the ACUITY and TIMI Major Bleeding Definitions on One-Year Mortality in Patients with Acute Coronary Syndromes (2007) (0)
Coronary heart disease Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes (2006) (0)
FREQUENCY, CLINICAL AND ANGIOGRAPHIC CHARACTERISTICS, AND OUTCOMES OF HIGH-RISK NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES PATIENTS WITH LEFT CIRCUMFLEX CULPRIT LESIONS (2012) (0)
PM225 Utility of High-Sensitivity Troponin To Diagnose Myocardial Infarction After Isolated Aortic Valve Replacement (2014) (0)
revalence , Predictors , and Impact of onservative Medical Management for Patients ith Non – ST-Segment Elevation Acute Coronary yndromes Who Have Angiographically Documented ignificant Coronary Disease (2008) (0)
Clopidogrel pretreatment versus clopidogrel exposure prior to PCI in the ACUITY Trial: Does it really matter? (2007) (0)
Rationale and Design for the Myocardial Ischemia and Transfusion (MINT) Randomized Clinical Trial. (2022) (0)
Electrocardiographic Left Ventricular ‘Strain’ Predicts Early Left Ventricular Dysfunction in Asymptomatic Aortic Stenosis (2007) (0)
THE EFFICACY AND SAFETY OF CANGRELOR WITH AND WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POOLED ANALYSIS OF THE CHAMPION TRIALS (2016) (0)
Significant Delays to Access Cardiac Angiography for Acute Coronary Syndrome (ACS) Patients in New Zealand (NZ): A Comparison of the National 2002, 2007 and (Snapshot) 2012 ACS Audits (2013) (0)
Management of ST-elevation myocardial infarction (2011) (0)
Utility of High-sensitivity Troponin T After Coronary Artery Bypass Grafting to Diagnose Peri-operative Myocardial Infarction and to Predict Mortality (2013) (0)
A new definition of MI: what does it mean? (2002) (0)
Hypertension and the risk of adverse cardiovascular outcomes following myocardial infarction: the VALIANT experience (2004) (0)
Heart failure post-myocardial infarction in the new millennium: how often does it occur, can we predict it, and what are the consequences? (2004) (0)
2170Screening multiple biomarkers for associations with cardiovascular death in patients with stable coronary heart disease (2018) (0)
Thrombolytic therapy for acute myocardial infarction: where are we now? Where should we go? (1995) (0)
Prognostic Utility of Bleeding Risk Scores in Acute Coronary Syndrome: A Meta-Analysis (2017) (0)
Abstract 14185: Heart Failure Occurring at any Time During Hospitalization is Associated with Higher Mortality in Non-ST Elevation-Acute Coronary Syndromes (2011) (0)
Possible beneficial interaction between statins and combination anglotensin receptor blocker (ARB) and ACE inhibitor treatment in patients with myocardial infarction: A post hoc analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT) (2005) (0)
Antecedent angina pectoris predicts worse outcome after thrombolytic therapy for acute myocardial infarction (1992) (0)
Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention – Insights from the CHAMPION program (2021) (0)
Improving Interventional Management of Acute Coronary Syndrome (ACS) Patients in New Zealand (NZ): A Comparison of the 2002, 2007 and 2012 National ACS Audits (2013) (0)
Relation between blood pressure after an acute coronary event and subsequent cardiovascular risk (2002) (0)
Disparities of outcomes between Pacific Island and European patients undergoing coronary artery bypass grafting (2014) (0)
Are reasons for socioeconomic and between country differences in cardiovascular mortality the same (2003) (0)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2019) (0)
Elevation of aspartate aminotransferase predicts mortality after coronary artery bypass grafting (2014) (0)
Utility of EuroSCORE I, EuroSCORE II and AusSCORE for Coronary Artery Bypass Grafting in a Contemporary New Zealand Cohort (2013) (0)
Modest Improvement of Reperfusion Times Across Multiple ST-Segment-Elevation Myocardial Infarction Networks With Rapid Care Process Implementation but no Effect on Mortality. (2017) (0)
Contrast-Induced Nephropathy Redefined; Impact of Any Acute Kidney Injury on Clinical Outcomes in Patients with ACS undergoing Angiography: Results from the ACUITY Trial (2008) (0)
Significance of Gender Discrepancies in Mortality Rates After Coronary Artery Bypass Grafting (2013) (0)
Surgical Risk Scores for Coronary Artery Bypass Grafting: with Focus on AusSCORE I and II (2018) (0)
Abstract 13938: Relationships Between ‘Mediterranean’ and ‘Western’ Dietary Patterns and Biomarkers Associated With Increased Cardiovascular Risk in Patients With Stable Coronary Heart Disease in the Global STABILITY Trial (2015) (0)
arfarin Use and Outcomes in Patients with Atrial ibrillation Complicating Acute Coronary Syndromes (0)
Coronary heart disease aVR ST elevation : an important but neglected sign in ST elevation acute myocardial infarction (2010) (0)
Cardiogenic shock without flow-limiting angiographic coronary artery disease: (from the Should We Emergently Revascularize Occluded Coronary Arteries for Cardiogenic Shock Trial and Registry). (2009) (0)
A LOW FRAMINGHAM RISK SCORE DOES NOT CONFER PROTECTION FROM AN ACUTE CORONARY SYNDROME: IMPLICATIONS FOR RISK ASSESSMENT IN YOUNG PEOPLE (2008) (0)
Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction - Results from the Valsartan in Acute Myocardial Infarc (2005) (0)
Prevention of reinfarction using half-dose reteplase and abciximab: observation from the GUSTO-5 trial (2002) (0)
Abstract 986: Hematomas of at Least 5 Cm and Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention: Insights From The STEEPLE Trial (2008) (0)
Delays in patients waiting for in-hospital angiography and CABG results in significant health care cost (2009) (0)
Characterization of cardiovascular endpoints, impact of event adjudication and effects of darapladib in the STABILITY trial (2015) (0)
Higher Allelic Frequency of Variants at the 9p21 Locus in Maori and Pacific Islanders Presenting With Severe Coronary Artery Disease (2009) (0)
3111Genetic variability in PAR4 platelet response in relation to bleeding and ischemic outcomes: a genetic substudy of the TRACER trial (2017) (0)
Myocardial Infarction Treated With Thrombolysis : Results From GUSTO-I Risk Factors for In-hospital Nonhemorrhagic Stroke in Patients With Acute (1998) (0)
Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. (2022) (0)
Response to NZMJ editorial by Dr Elana Curtis entitled Deserving of more: framing of Māori inequities in cardiovascular care remain a challenge. (2013) (0)
P6249Screening multiple biomarkers for associations with acute ischemic stroke in patients with stable coronary heart disease (2018) (0)
Absolute and relative truth in clinical trials. Authors' reply (2002) (0)
Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome. (2023) (0)
Abstract 3302: Outcomes in Elderly Patients Treated with Bivalirudin Monotherapy Versus Glycoprotein IIb/IIIa Inhibitors with Heparin or LMWH: Results from the Randomized ACUITY Trial (2006) (0)
Letter to the Editor—A Charge to Radiology Nurses: Make Them See You (2007) (0)
Prognostic value of post-operative aspartate aminotransferase levels after isolated coronary artery bypass grafting and isolated isolated aortic valve replacement (2015) (0)
Abstract 6083: Sex Differences in 1-Year Mortality Following Acute Coronary Syndromes (2008) (0)
Versus Unfractionated Heparin in lective Percutaneous Coronary Intervention-Year Results From the STEEPLE ( SafeTy and Efficacy of noxaparin in Percutaneous coronary intervention patients , n internationaL randomized Evaluation ) Trial (0)
Value of expert opinion in recommending early intensive lipid lowering in patients with ACS. (2022) (0)
Epidemiology of Heart Failure (2008) (0)
Abstract 6179: Baseline Q Trumps Time from Symptom Onset as a Prognostic Marker in STEMI Patients Treated with Primary PCI (2008) (0)
Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes Clinical Investigation and Reports (2001) (0)
Who is at risk of early Hypotension and renal dysfunction with an inhibitor of the Renin Angiotensin System after myocardial infarction? data from VALIANT (2004) (0)
Electrocardiography in acute coronary syndromes (2012) (0)
ST recovery in the lead with maximum ST elevation at baseline is more closely associated with late survival after myocardial infarction (2003) (0)
Abstract 12130: Outcomes in Women Compared With Men in Patients With Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction Managed Without Revascularization: Insights From the TRILOGY ACS Trial (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Harvey Douglas White?

Harvey Douglas White is affiliated with the following schools:

Harvey Douglas White's Academic­Influence.com Rankings

Harvey Douglas White's Degrees

Similar Degrees You Can Earn

Why Is Harvey Douglas White Influential?

Harvey Douglas White's Published Works

Published Works

What Schools Are Affiliated With Harvey Douglas White?

Harvey Douglas White's AcademicInfluence.com Rankings